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Abstract
Polycystic ovarian syndrome (PCOS) is a highly prevalent heterogeneous syndrome
associated with abdominal obesity, insulin resistance and the metabolic syndrome. This
clustering of risk factors could translate into an adverse cardiovascular disease (CVD) risk
profile. Endothelial dysfunction, an early barometer of CVD, has been exhibited by women
with PCOS; however, it remains unclear whether endothelial dysfunction is independent of
CVD risk factors in this population, Exercise training has been found to enhance conduit
artery and cutaneous microvessel endothelial function in various populations. Nevertheless,
limited research exists regarding the cardiovascular effects of exercise in PCOS, and its
impact on endothelial function in conduit arteries and cutaneous microvessels, has not been
explored. The primary aim of this thesis was to examine nitric oxide (NO)-mediated
endothelial function at different levels of the vascular tree in women with PCOS and to
establish whether supervised exercise training induces a therapeutic effect on endothelial
function.
A systematic review of published studies comparing FMD in PCOS and control women
was conducted. Twenty-one published studies were identified for inclusion (PCOS n=908;
controls n=566). Differences in FMD between PCOS and controls were synthesised and
meta-regressed against BMI and age. The pooled mean FMD was 3.5% lower (95% CI=3.4,
3.7%; P<O.OOI) in women with PCOS compared with controls; and the PCOS-mediated
reduction in FMD was most evident in studies involving less obese women.
PCOS [n=35, 28y (95% CI=26, 30), 31kg/m2 (95% CI=27, 35)] and control women [n=16,
32y (95% CI=30, 35), 30kg/m2 (95% CI=25, 32)] were recruited. Brachial artery
endothelial function was assessed using flow-mediated dilation (FMD). Internal adipose
tissue (lAT), subcutaneous (SAT), visceral (VAT) and abdominal SAT was quantified
using whole body magnetic resonance imaging and IH magnetic resonance spectroscopy
quantified liver and skeletal muscle fat. Cardiorespiratory fitness, glycaemic control,
reproductive hormone and lipid profiles were also assessed. FMD was impaired in PCOS
when compared with control women [-4.5% (95% CI=-6.3, -2.8), P<O.OOl]. When FMD
was adjusted for individual differences in IAT [-4.3% (95% CI=-6.l, -2.4), P<O.OOl], VAT
[-4.4% (95% CI=-6.3, -2.5), P<O.OOl] and insulin resistance [-3.9% (95% CI=-5.6, -2.1),
P<O.OO 1], the difference in FMD between groups remained.
Ten women with PCOS [27y (95% CI=23, 32), 31 kg/rrr' (95% CI=28, 34)] completed a
16-week supervised exercise programme while 7 women with PCOS [29y (95% CI=24,
35), 35kg/m2 (95%CI=31, 40)] opted for conventional care and followed simple lifestyle
advice. Exercise training improved FMD to a greater degree than conventional care [3.4%
(95% CI=1.8, 5.1), P>0.0005] and in parallel greater improvements in cardiorespiratory
fitness were observed with exercise [4.7ml/kg/min (95% CI=1.4, 7.9), P=0.005]. These
changes with exercise occurred independently of changes in VAT, SAT or insulin
resistance.
NO-mediated vasodilation in the cutaneous microvessels was examined in 11 PCOS [29y
(95% CI=25, 34), 34kg/m2 (95% CI=30, 38)] and 6 control women [29y (95% CI=21, 37),
34kg/m2 (95% CI=28, 39)] using laser Doppler flowmetry combined with intra-dermal
microdialysis of L-NG-monomethyl arginine to assay the NO dilator system in response to
incremental local heating of the forearm. Six women with PCOS [30y (95% CI=22, 37),
31kg/m2 (95% CI=25, 37)] then undertook a 16-week exercise-training programme. Nitric
oxide contribution was attenuated in women with PCOS at peak heating [-16.0CVCmax (95%
CI=-32.5, 0.6), P=0.05] and during prolonged maximal heating [-15.4CVCmax (95% CI=-
29.6, -1.3), P=0.04], compared with control women. Cardiorespiratory fitness improved by
5.0ml/kg/min (95% CI=0.9, 9.2) following exercise training (P=0.03). This was
accompanied by increased NO contribution to cutaneous blood flow between 36.5-42°C
(P<0.05), at peak heating [19.6CVCmax (95% CI=4.3, 34.9), P=0.02] and during prolonged
maximal heating [17.1CVCmax (95% CI=2.2, 32.2), P=0.03].
The findings from this thesis suggest that endothelial dysfunction is an intrinsic
characteristic of PCOS and that supervised exercise training enhances endothelial function
in both conduit vessels and cutaneous microvessels, independent of adiposity or traditional
CVD risk factors. The direct impact of exercise training on the vasculature of women with
PCOS may decrease the risk of CVD morbidities, such as hypertension, and consequently
reduce cardiovascular mortality in post-menopausal years.
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CHAPTERl
INTRODUCTION
Polycystic Ovarian Syndrome (PCOS) is a condition characterised by clinical or
biochemical hyperandrogenism, oligo-/amenorrhea and polycystic appearance of the
ovaries upon ultrasound examination (Goodarzi et al., 2011). Although traditionally
considered a reproductive disorder, in recent years, the complex heterogeneous phenotype
of PCOS has been found to encompass obesity, insulin resistance and androgen excess.
Therefore, PCOS has become an increasing concern for many aspects of women's health.
Nevertheless, the precise aetiology of PCOS remains unclear with both genetic
predisposition and environmental influences being implicated (Legro, 1995). Alarmingly,
PCOS is the single most common endocrinopathy in females, affecting approximately 10%
of premenopausal women globally.
Women with PCOS are generally more obese than their age matched non-PCOS
counterparts, evidenced by an elevated body mass index (BMI) and waist circumference
(Talbott et al., 1995; Gambineri et al., 2002). Specifically, when compared with weight
matched controls, women with PCOS display a similar volume of total body fat but a
higher volume of central abdominal fat (Carmina et al., 2007b) and elevated visceral
adipose tissue (VAT) (Yildirim et al., 2003). Central obesity is a well-established risk
factor for metabolic dysfunction in PCOS (Lord et al., 2006) and, furthermore, increased
VAT is closely associated with insulin resistance (Hutchison et al., 2011) and seems to be
predictive of cardiovascular disease (CVD) (Cascella et al., 2008a), specifically
atherosclerosis (Grundy, 2002). This CVD risk profile is further exacerbated by atypical
blood lipid profiles, with suppressed high density lipoproteins and elevated triglycerides,
frequently being expressed in women with PCOS (Wild et al., 1985; Talbott et al., 1995).
Given the range and prevalence of co-morbidities evident in women with PCOS, the
condition has been described as a gender-specific phenotype of the metabolic syndrome
(Expert Panel on DetectionEvaluation, 2001), which is associated with a ~2 fold increased
risk of cardiovascular mortality (Alberti, 2006).
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Over the past two decades an association between PCOS and CVD has been recognised.
This relationship is evidenced by a systematic review and meta-analysis performed by de
Groot et al. (2011) who investigated the risk of CVD and cardiovascular events in women
with PCOS. The study classified PCOS as an independent risk factor for CVD and
identified a -2 fold increased risk of coronary heart disease and stroke. Indeed, PCOS has
been acknowledged as a risk factor for CVD by the American Society for Reproductive
Medicine Practice Committee (2008b). Nonetheless, while evidence is suggestive of
increased CVD risk (Talbott et al., 2000; Wild et al., 2000), the association between PCOS
and CVD mortality remains equivocal, since evidence of increased cardiovascular events is
limited.
Several risk factors evident in women with PCOS, are associated with endothelial
dysfunction. Endothelial dysfunction is an important early event in the development of
atherosclerotic disease, which precedes gross morphological signs and clinical symptoms.
Specifically, endothelial dysfunction is characterised by impaired bioavailability of the
anti-atherogenic molecule nitric oxide (NO), a critical component in endogenous
protection against atherosclerosis. Endothelial dysfunction in conduit vessels of women
with PCOS, manifest as reduced flow-mediated dilation (FMD), has been observed in
some (Cascella et al., 2008a), but not all, previous studies (Beckman et al., 2007). In the
few studies investigating cutaneous endothelial function in women with PCOS, cutaneous
microvessel dysfunction has been observed (Lakhani et al., 2005; Alexandraki et al., 2006)
although, more recently, Ketel et al. (2008) found similar cutaneous microvessel
vasodilator function in obese women with PCOS and controls. Moreover, the underlying
mechanism(s) that directly mediate conduit artery and cutaneous microvessel endothelial
dysfunction in PCOS are incompletely understood.
3
Treatment of peos is complex, as clinical manifestations vary considerably and thus
current pharmacological treatments are limited. Therefore, lifestyle modification, including
exercise training, is recommended as a primary prevention strategy of eVD by the
androgen excess-Pf'Ofi consensus statement (Wild et al., 2010; Harrison et al., 2011).
Exercise has been shown to improve the structure and function of vascular endothelial cells
and thus offset the development of atherosclerosis in individuals with type 2 diabetes
(Maiorana et al., 2001), obesity (Watts et al., 2004), coronary artery disease (Walsh et al.,
2003) and metabolic syndrome (Hamdy et al., 2003). Nevertheless, no previous research
has compared the therapeutic effect of exercise interventions alone with that of the general
lifestyle advice (weight loss via increased physical activity and diet) provided as part of
conventional clinical care. Moreover, the effects of exercise training on NO-mediated
microvessel endothelial function in women with peos have yet to be explored.
In summary, there is some evidence of endothelial dysfunction in women with peos.
Nevertheless, there is considerable disparity within the existing literature that may relate to
considerable inter-subject variability, with different definitions of diagnosis, disease
duration, disease severities, and co-morbidities or to poorly matched control groups.
Therefore, the potential underlying mechanisms contributing to endothelial function in this
population are incompletely understood. Despite the high prevalence of eVD risk (Wild et
al., 2000), which extends into the post-menopausal years (de Groot et al., 2011), no study
has, to date, investigated the effects of exercise training on NO-mediated conduit artery or
cutaneous microvessel endothelial function in women with peos.
Aims
Thus, the aims of this thesis are to:
1. Examine the prevalence and extent of endothelial dysfunction, measured using the
FMD technique, in women with peos according to pre-existing scientific
literature, and explore the influence of between-study moderators, such as age, BMI
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and diagnostic criteria, on the difference in FMD between PCOS and control
women.
2. Investigate the impact of adipose tissue volumes on endothelial function in women
with PCOS.
3. Compare the effect of a supervised 16-week moderate-intensity aerobic exercise
training programme with conventional clinical care on conduit artery endothelial
function in women with PCOS.
4. Investigate cutaneous NO-mediated endothelial function m women with PCOS
compared with matched controls.
5. Examine the effect of a supervised 16-week moderate-intensity aerobic exercise
training programme on NO-mediated cutaneous microvessel endothelial function in
women with PCOS.
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CHAPTER2
LITERATURE REVIEW
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2.1 Polycystic Ovarian Syndrome
Polycystic ovarian syndrome (PCOS), originally known as the Stein-Leventhal syndrome,
was first described in the 1930's. Stein and Leventhal detailed findings based on seven
women with amenorrhea, hirsutism, and polycystic appearance of the ovaries and, in doing
so, were the first to depict the triad of clinical characteristics that typify PCOS in its
complete phenotype (1935). Today, PCOS is regarded as a heterogeneous syndrome
consisting of hyperandrogenism, menstrual dysfunction and the presence of ovarian cysts
upon ultrasound examination (Ehrmann, 2005; Franks, 2006).
2.1.1 Aetiology and Pathogenesis
Traditionally, PCOS was primarily considered a reproductive disorder. Polycystic ovaries,
anovulation and consequent sub-fertility is common among women with PCOS (2008a)
and can translate to an increased risk of miscarriage (Cano et al., 1997) or infertility
(Norman et al., 2004). In recent times, a complex heterogeneous phenotype of PCOS,
encompassing obesity, insulin resistance and androgen excess, has emerged. Currently, the
precise aetiology of PCOS remains unclear with both genetic predisposition and
environmental influences being implicated (Legro, 1995); therefore, theories alluding to
the pathogenesis of PCOS remain hypothetical.
Women with PCOS are more obese than age-matched controls, demonstrating not only an
elevated body mass index (BMI), a proxy of global obesity, but also a greater waist: hip
ratio (WHR), an anthropometric measure of central obesity (Talbott et al., 1995). Women
with PCOS generally display similar volumes of total body fat, but have been found to
exhibit increased visceral adipose tissue (VAT) (Yildirim et al., 2003). VAT is adipose
tissue that is stored around the internal organs located in the abdomen and is strongly
associated with insulin resistance in women with PCOS (Hutchison et aI., 2011). Insulin
resistance is a common pathophysiological feature of PCOS, which is potentially a
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consequence of elevated adipose tissue, and specifically of VAT. However, the molecular
mechanisms underlying insulin resistance in peas are incompletely understood, although
defects in insulin mediated glucose transport (Ciaraldi et aI., 1992), GLUT4 production
(Ciaraldi et al., 2009) and insulin-regulated lipolysis in adipocytes (Ciaraldi, 2000) have
been reported. Insulin resistance results in compensatory hyperinsulinemia to maintain
normal glucose levels but, in doing so, adversely affects ovarian androgen production.
More recently, insulin resistance has been considered a pivotal feature of peas with
approximately 50-70% of women with peas exhibiting insulin resistance beyond that
usually predicted by BMI (DeUgarte et al., 2005). Insulin resistance causes pancreatic p
cells to secrete more insulin in order to maintain euglycaemia, resulting in compensatory
hyperinsulinemia which drives many of the phenotypic features of peas (Zawadzki &
Dunaif, 1992). Notably, hyperinsulinemia promotes ovarian hyperandrogenism (Moghetti
et al., 2000) and amplifies the secretion of LH. Insulin acts synergistically with LH to
enhance androgen production and inhibits hepatic synthesis of sex hormone binding
globulin (SHBG) (a circulating hormone that binds to testosterone), leading to androgen
excess (Bergh et al., 1993). This atypical ovarian paracrine signalling disrupts follicle
growth and causes menstrual irregularities with resultant chronic anovulation and the
accumulation of small follicles on the periphery of the ovary (polycystic morphology)
(Balen et al., 1995). Hyperandrogenism is also considered as a central feature of peas, as
approximately 85% of hyperandrogenic women suffer from the syndrome (Azziz et al.,
2009). Androgen excess can be assessed biochemically although cutaneous manifestations
of hyperandrogenemia are also apparent in women with peas including acne, hirsutism
and male pattern alopecia (Ehrmann, 2005).
Obese and insulin resistant women with peas often exhibit a concomitant set of risk
factors, which together epitomise the metabolic syndrome. Indeed, peas has been
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described as a gender-specific phenotype of the metabolic syndrome (Expert Panel on
r
DetectionEvaluation, 2001). This clustering of risk factors (including metabolic,
biochemical and physiological abnormalities) confer substantial cardiovascular risk which
exceeds the sum of the risk associated with each abnormality alone (Golden et al., 2002).
2.1.2 Diagnosis and Clinical Manifestations
The symptoms of peos typically become apparent at the onset of menarche (Franks,
2002). Traditional diagnosis of peos was based on polycystic or enlarged ovaries (Figure
2.1) and the identification of abnormal gonadotropin secretion that invariably manifests in
women with peos (Waldstreicher et al., 1988). Gonadotropins are protein hormones
secreted by gonadotrope cells of the pituitary gland, including follicle stimulating hormone
(FSH) and luteinizing hormone (LH) which fluctuate significantly over the course of the
menstrual cycle. Ultrasound assessment and accurate diagnosis of polycystic ovaries is
complex and the most commonly used criteria are those proposed by Jonard et al. (2003).
Polycystic ovaries can be established when at least one ovary demonstrates an enlarged
ovarian volume (>1Ocnr') or> 12 follicles measuring between 2-9mm in diameter.
Normal Ovary
Figure 2.1 Illustration of a healthy and polycystic ovary and polycystic appearance of the
ovary upon ultrasound examination.
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Still today, there is not a universal diagnostic criterion for defining PCOS, as symptoms are
heterogeneous, vary significantly over time and differ in severity from patient to patient.
Currently, there is one biological definition of PCOS, published by the World Health
Organisation (Organization, 1973), and three consensus definitions in widespread use
(Table 2.1). The first was defined at proceedings sponsored by National Institute of Health
(NIH) and summarised by Zawadski and Dunaif (1992). This definition identifies
hyperandrogenism as the key feature of PCOS (following exclusion of other
hyperandrogenic disorders) with accompanying oglio-ovulation. In 2003, an expert
convention was convened in Rotterdam and concluded that PCOS should be diagnosed
based on the presence of two of the following three features i) clinical or biochemical
hyperandrogenism (having excluded other possible causes by appropriate biochemical
assessments), ii) oligo-/amenorrhoea, iii) polycystic ovaries (2004). More recently, the
androgen excess society (AES) defined PCOS as an androgen excess disorder (Azziz et aI.,
2006). The task force recognised four key features of PCOS including, (i) ovulatory and
menstrual dysfunction, (ii) hyperandrogenemia, (iii) clinical features of hyperandrogenism
and (iv) polycystic ovaries. Despite lengthy debate among clinicians and academics
regarding the definition of PCOS, it is widely accepted that the definition will continue to
evolve in coming years to incorporate new research findings. Current clinical guidelines in
the UK utilise the Rotterdam criteria for diagnosing PCOS.
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Table 2.1 A comparison of consensus diagnostic criteria for peos (Lujan et al., 2008).
2.1.3 Prevalence & Epidemiology
Worldwide, peos affects up to 10% of women of reproductive age (Azziz et al., 2004;
Manfredi et al., 2006) according to the 'classical' NIH criteria (Gazelle et al., 1994); and
up to 20% of women according to the broader Rotterdam criteria (Broekmans et al., 2006).
Based on this statistic, peos is the single most common endocrinopathy in women of
reproductive age. Interestingly, the prevalence of peos is similar in various populations
worldwide (Diamanti-Kandarakis et al., 1999; Asuncion et al., 2000; Azziz et al., 2004;
Moran et al., 2010a) suggesting that peos is a unique disorder, that manifested prior to
human migration, and is not solely lifestyle-induced.
peos appears to be more prevalent among family members than in the general population
(Legro et al., 1998; Kahsar-Miller et al., 2001). Heritability for peos ofO.71 was reported
in Dutch twins suggesting that genetic factors do influence the prevalence of the syndrome
(Vink et al., 2006). Heritability of a population is an estimate of how much genetics
contribute to the prevalence of a characteristic. peos appears to be inherited as a complex
disorder, wherein several genetic variants are implicated in the development of the disorder
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(Goodarzi et al., 2011). The phenotypic expression of PCOS can be exacerbated by
lifestyle and environmental influences (Moran & Teede, 2009) which ultimately increases
the likelihood of cardiovascular and metabolic complication (Carmina et al., 2005).
2.2 Metabolic features of PCOS
The long term morbidities associated with PCOS extend far beyond the reproductive axis;
PCOS is associated with several cardiovascular and metabolic pathologies including
obesity, insulin resistance, impaired glucose tolerance, type 2 diabetes, non-alcoholic fatty
liver disease (NAFLD), dyslipidaemia and hypertension (Goodarzi et al., 2011).
Consequently, it might be expected that cardiovascular disease (CVD) would be highly
prevalent in women with PCOS (Glueck et al., 2003). The clustering of CVD risk factors
that characterises the metabolic syndrome (see section 2.2.3 The Metabolic Syndrome) is
thought to be the driving force behind the CVD epidemic in Western society. Indeed, it is
estimated that individuals with the metabolic syndrome encompass a -5 fold greater risk of
developing type 2 diabetes and are -3 times more at risk of mortality due to myocardial
infarction or stroke, when compared to individuals without the syndrome (Stem et al.,
2004). The high prevalence of metabolic co-morbidities in women with PCOS is not
surprising, since insulin resistance and central obesity are fundamental pathogenic features
of both PCOS and the metabolic syndrome.
2.2.1 Obesity and Adipose Tissue
Women with PCOS generally display elevated global (BMI) and central obesity (waist
circumference) compared with matched control women. This is associated with several risk
factors for coronary heart disease (CHD) and atherosclerosis (Talbott et al., 1995;
Gambineri et al., 2002). The incidence of obesity in PCOS varies geographically, the obese
phenotype being most common in Westernised society (Knochenhauer et al., 1998). When
compared with weight-matched controls, women with PCOS display a similar volume of
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total body fat but a higher volume of central abdominal fat (Carmina et al., 2007b) and
VAT (Yildirim et al., 2003). Yildrim et al. (2003) assessed VAT in 30 healthy weight
peos and 30 matched control women and reported a significantly higher volume in the
peos cohort. This study utilised ultrasound for the assessment of VAT which, although it
has well accepted limitations, has been reported to correlate with computed tomography
(Armellini et al., 1990). There was also evidence of glucose intolerance, hyperinsulemia
and atypical blood profiles, namely raised triglycerides and reduced high density
lipoproteins (HDL), despite the absence of obesity. Interestingly, multiple regression
analysis revealed that VAT significantly contributed to hyperinsulinemia and triglyceride
concentration. Based on Yildrim' s findings, it could be hypothesised that VAT
accumulation increases circulating triglycerides, which act as a stimulus to increase hepatic
secretion of glucose and therein contribute to hyperinsulemia in women with peos. Thus,
VAT is considered a pivotal and early feature of metabolic disturbance in women with
peos, independent of obesity. However, using the non-invasive gold standard MRI, VAT
has been reported to be similar among overweight and obese peos and weight-matched
women (Barber et al., 2008).
Although subcutaneous adipose tissue (SAT) accounts for a greater volume of total body
fat, VAT is more metabolically active and therefore more susceptible to lipolysis
(Montague & O'Rahilly, 2000); hence VAT has been described as an endocrine source of
circulating free fatty acids (FFA). A unique anatomical feature of VAT is that it is drained
via the portal vein, whereas SAT secretes adipokines into the systemic circulation
(Matsuzawa et al., 1995). Thus, VAT has been hypothesised to deliver high concentrations
of FFA directly to the liver (see section 2.2.4 Non-Alcoholic Fatty Liver Disease) thereby
contributing to hyperinsulinaemia by driving hepatic gluconeogenesis (Fujioka et al.,
1987). Indeed, excess VAT accumulation is also responsible for the up-regulation of ~
oxidation which results in subsequent oxidative stress, the release of inflammatory
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cytokines (fibrinogen, WBC, CRP & PAl-I) and adipokines (leptin, visfatin & TNFa) and
a reduction of endogenous adiponectin, an anti-inflammatory substance (Carmina et al.,
2006; Cascella et al., 2008a; Carmina et al., 2009; Pepene, 2012).
Recently, Hutchison et al. (2011) confirmed the relationship between VAT and insulin
resistance, following statistical adjustment for age, in women with pcas. This relationship
was identified using the gold standard technique for assessing insulin resistance
(euglycaemic clamp) and computer tomography assessment of VAT. A hyperinsulinaemic
euglycaemic clamp quantifies insulin resistance by measuring the amount of glucose
required to compensate for increased insulin levels. The concentration of insulin can be
manipulated to assess either peripheral or hepatic insulin action. Moreover, it was reported
that elevated VAT is predictive of CVD in post-menopausal women and obesity has been
specifically linked to an increased likelihood of atherosclerosis in both men and women
(Grundy, 2002). Furthermore, raised glycohaemoglobin, which reflects insulin resistance,
was observed in men and women exhibiting greater adiposity (McGill et al., 2002). Taken
together, these findings support the hypothesis that obesity is a risk factor for
atherosclerosis in women and that emerging risk factors related to obesity, such as insulin
resistance, are atherogenic.
2.2.2 Insulin resistance
Insulin resistance is often associated with the pathogenesis of pcas and can be intensified
by co-existent obesity (Dunaif et al., 1989). pcas and obesity together attribute the
greatest impairment in insulin sensitivity, indeed, insulin resistance is apparent in 50-70%
of women with pcas and in 95% of obese women with pcas (Carmina & Lobo, 2004).
This augmented insulin resistance has been identified as a potential contributor to the
development of type 2 diabetes (Norman et al., 2001) and subsequent CVD risk within this
patient group (Meyer et al., 2005c). Both insulin resistance and the progression to type 2
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diabetes imply changes in lipid metabolism and a plethora of cardiovascular risk factors.
This association is depicted by Folsom et al. (1997) who demonstrated a linear increase in
eVD risk across quintiles of fasting insulin in non-diabetic women (Figure 2.2).
Figure 2.2 Sex-specific, age- and race-adjusted incidence of eHD in relation to fasting
serum insulin concentrations among people without diabetes in the atherosclerotic risk in
communities study. Values within the bars represent the relative risk of eHD for that
insulin category referenced to the lowest category (Folsom et al., 1997).
Boudreaux et al. (2006) conducted an 8-year follow up in women with peos to determine
the magnitude of risk in developing type 2 diabetes. Women with peos, defined using the
Rotterdam criteria, demonstrated an increased relative risk of type 2 diabetes of -2.3
compared with matched control women. Increasing age and weight gain significantly
worsened glycaemic control as obese women with peos were -5 times more likely to
develop type 2 diabetes, following statistical adjustment for age. These findings were in
agreement with a systematic review and meta-analysis of 35 studies investigating the
prevalence of glucose intolerance and type 2 diabetes in women with peos (Moran et al.,
2010b). The authors found an increased prevalence of glucose intolerance, type 2 diabetes
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and the metabolic syndrome in both BMI-matched and unmatched studies. Specifically,
PCOS was associated with a -2.5 fold increased prevalence of impaired glucose tolerance
and a -4 fold increased prevalence of type 2 diabetes, suggesting that insulin resistance is
an inherent feature of PCOS, independent of obesity.
2.2.3 The Metabolic Syndrome
The relationship between PCOS, type 2 diabetes and CVD is well established. The cluster
of CVD risk factors which characterises the metabolic syndrome are highly prevalent in
both PCOS and type 2 diabetic patients (Alberti, 2006). According to the latest
International Diabetes Federation definition (2006), for an individual to have the metabolic
syndrome they must demonstrate central obesity (defined as waist circumference with
specific ethnicity values) plus any two of the following; raised triglycerides (2::1.7mmol/l),
reduced HDL cholesterol «1.29mmol/l In females), raised blood pressure
(SBP2::130mmHg,DBP2::85mmHg) and/or raised fasting glucose (5.6mmol/l). Hu et al.
(2004) conducted a thorough review based on 11 prospective European cohort studies
(with a median follow-up of 8.8 years) comprising 6156 men and 5356 women, without
diabetes, aged 30-89 years. Presence of the metabolic syndrome was based on a revised
WHO definition (1998) and the authors found that the more components of the metabolic
syndrome evident in a given individual, the higher the rate of cardiovascular related
mortality. Components of the metabolic syndrome observed in women with PCOS include;
abdominal obesity (Valenzuela et al., 2006), insulin resistance (Teede et al., 2007),
dyslipidaemia (Legro et al., 2001) and hypertension (Meyer et al., 2005b). Therefore,
rather unsurprisingly, women with PCOS encompass an adverse cardiovascular risk profile
(Diamanti-Kandarakis et al., 2006; Ketel et al., 2010).
Dyslipidaemia is the most common metabolic pathology of PCOS with a prevalence of up
to 70% (Legro et al., 2001). In particular, suppressed HDL and elevated triglycerides is an
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atypical blood lipid profile frequently expressed in women with PCGS (Wild et al., 1985;
Talbott et al., 1995), which is indicative of the metabolic syndrome. This dyslipidaemia is
thought to stem from increased adiposity, particularly visceral adiposity, which can be
reflected by an increased waist circumference (Expert Panel on DetectionEvaluation, 200 I).
Conversely, the presence of raised blood pressure in young women with PCGS is unclear
(Conway et al., 1992; Sampson et al., 1996). Schmidt and colleagues (2011) recently
conducted a 21-year follow up study and reported a higher prevalence of hypertension in
PCGS compared with age- and BMI-matched control women during the post-menopausal
period, suggesting that this component may occur with increasing age.
2.2.4 Non-Alcoholic Fatty Liver Disease
Women with PCGS have a higher prevalence of fat deposition in the liver, a condition
coined Non-Alcoholic Fatty Liver Disease (NAFLD) (Brzozowska et al., 2009). NAFLD
represents a disease spectrum, ranging from hepatic steatosis, characterised by deposition
of triglycerides in the hepatocytes, through to non-alcoholic steatohepatitis (NASH),
characterised by inflammation and fibrosis, which can in turn progress to cirrhosis (Cohen
et al., 2011). NAFLD is the most common form of liver disease in the western world, with
a prevalence of up to -70-90% in obese individuals and individuals displaying components
of the metabolic syndrome (Marchesini et al., 2005), and encompasses significant CVD
risk (Ekstedt et al., 2006). Based on the prevalence of clinical biomarkers such as liver
transaminases or ultrasonography to infer the presence of hepatic steatosis, a number of
studies have demonstrated a high risk of hepatic steatosis in women with PCGS (Setji et al.,
2006; Cerda et al., 2007; Vassilatou et al., 2010; Baranova et al., 2011). Gutierrez et al.
(2010) identified an increased probability ofNALFD in women with PCGS compared with
pre- and postmenopausal women (Figure 2.3). PCGS and NAFLD are both associated with
cardiovascular risk factors including central obesity, dyslipidaemia and hypertension, but
the most common pathology present in both conditions is insulin resistance.
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Figure 2.3 The predicted probability of NAFLD (95% confidence intervals) in
premenopausal, postmenopausal and women with peGS, statistically adjusted for the
presence of the metabolic syndrome (Gutierrez-Grobe et al., 2010).
Fat accumulation within the liver is associated with both hepatic (Bugianesi et al., 2005)
and adipocyte insulin resistance (Fabbrini et al., 2009). In an insulin resistant state, the
inhibitory effect of insulin on peripheral adipose lipolysis is diminished and thereby causes
an influx in circulatory FFA and subsequent absorption of FFA by the liver. Additionally,
hyperinsulinaemia provokes an increase in de novo lipogenesis (Fabbrini et al., 2009),
which further adds to FFA accumulation in the liver. The current body of evidence
suggests that insulin resistance, a key pathophysiological feature of peGS, promotes liver
fat accumulation. Alarmingly, excess liver fat accumulation can also exacerbate peripheral
insulin resistance, via enhanced basal insulin secretion and decreased suppression of
hepatic glucose output, and thus generate a vicious cycle that can ultimately lead to
diabetes (Taylor, 2008) and, in tum, eVD.
2.3 PCOS and Cardiovascular Disease
The prevention of increasingly prevalent diseases such as eVD is a major public health
challenge. In the UK alone, 2.7 million people are living with CVD, which is currently the
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main cause of mortality accounting for approximately 191,000 deaths each year (Allender
et al., 2011). PCDS has been acknowledged as a risk factor for CVD by the American
Society for Reproductive Medicine (ASRM) Practice Committee (2008b). Further
supporting evidence for this association came from a systematic review and meta-analysis
performed by de Groot et al. (2011) investigating cardiovascular events in women with
PCDS. The authors identified PCDS as a risk factor for CVD and reported a -2 fold
increased risk of CHD and stroke. Moreover, this increased risk remained in the studies
that were statistically adjusted for BMI, demonstrating that increased obesity is not the sole
contributing factor of CVD risk in women with PCDS. Nevertheless, while existing
epidemiological evidence is suggestive of increased CVD risk (Talbott et al., 2000; Wild et
al., 2000) it is yet to be established whether PCDS per se and/or the presence of associated
cardiovascular risk factors translates into increased CVD mortality.
In 1992, Dahlgren and colleagues (1992) predicted a -7 fold increased risk of myocardial
infarction in women with PCDS, based on a metabolic risk factor model. However, this
research group have recently reported findings from a 21 year follow up study based on the
same cohort and reported an increased prevalence of CVD risk factors, including
hypertension and raised triglycerides, but a similar incidence of myocardial infarction and
diabetes related mortality in PCDS and age-matched control women (Schmidt et al., 2011).
Wild et al. (2000) conducted a 31 year follow up study whereby the research team collated
morbidity data from general practice records for 319 women diagnosed with PCDS (prior
to 1979) and 1060 age-matched control women. The authors did not report an increased
prevalence of either fatal or non-fatal cardiovascular events in women with PCDS,
although the prevalence of cardiovascular risk factors and the rate of non-fatal
cerebrovascular disease were higher. A much larger scale study found that 15% of 82,439
women experienced menstrual irregularity between the ages of 20-35y. Those with a
history of menstrual dysfunction exhibited an increased relative risk of fatal and non-fatal
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CHD of 1.25 and 1.67, respectively, and this relative risk remained following statistical
adjustment for BMI (Solomon et al., 2002). Furthermore, the Women's Ischemia
Evaluation Society reported an increased prevalence of angiographic coronary artery
disease (CAD) and an elevated risk of adverse cardiovascular events in post-menopausal
women displaying clinical features consistent with PCOS (Shaw et al., 2008).
It is of paramount importance to note that epidemiological studies on women with PCOS
are fundamentally limited by several recurring factors such as small sample sizes and
relatively short follow up periods resulting in a low mean age of the cohort. Furthermore,
not all studies have utilised the same diagnostic criteria or indeed any consensus definition
of PCOS. It is well accepted that PCOS phenotypes and subsequent risk profiles differ, and
thus findings from epidemiological studies must be interpreted with caution. Few studies
monitor treatment strategies utilised by women with PCOS during the course of the follow-
up period or comment on changing clinical phenotypes over time. Whether the predicted
increased risk of CVD mortality in women with PCOS is accurate remains to be confirmed
as studies investigating morbidity and mortality well into the postmenopausal period are
considerably lacking.
2.4 The Role of the Vascular Endothelium in Conduit Vessels
The arterial tree consists of an intricate network of blood vessels branching from the heart
to conduit arteries, arterioles and capillaries. Conduit vessels are characterised by a thick
tunica media that contains a greater amount of smooth muscle cells compared to other
branches of the arterial tree (Figure 2.4). The contractility of these vessels allows them to
actively vasodilate, under the influence of circulating vasoactive substances and under the
control of the sympathetic division of the autonomic nervous system. Arterioles have much
smaller internal diameters, which change in response to either sympathetic or endocrine
stimulation. Arterioles branch out from conduit vessels and extend to the capillaries (5-
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lOurn in diameter). Capillaries form an interconnected network, or bed, containing direct
connections between arterioles and venules and represent the only component of the
arterial tree which permits the diffusion of water, small solutes and lipid-soluble materials
into the surrounding interstitial fluid.
Capillary
Figure 2.4 The arterial tree from conduit vessels (arteries) through to capillaries.
A squamous epithelial layer lines the inner surface of all blood vessels, this is known as the
endothelium (Figure 2.4). Once considered a passive layer of inert cells, the vascular
endothelium is now recognised as large endocrine organ that lines the entire vascular
compartment at the interface between blood and the vessel wall which is responsible for
the maintenance of vascular tone. A healthy endothelium mediates anti-atherogenic
properties that protect against vasoconstriction, smooth muscle cell growth and
inflammatory responses (Davignon & Ganz, 2004). A healthy endothelium produces
numerous paracrine substances, including nitric oxide (NO), which help maintain the
health of the vascular wall and regulate vasomotor function (Green et al., 2004). NO is a
labile, lipid soluble gas synthesised in endothelial cells from the amino acid L-arginine
through the action of endothelial nitric oxide synthase (eNOS) (Palmer et al., 1988). It
rapidly diffuses into the vascular smooth muscle of the tunica media where it binds to the
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enzyme guanylate cyclase (Ignarro et aI., 1986), resulting in an increase in cyclic
guanosine monophosphate, which induces smooth muscle relaxation and subsequent
vasodilation (Furchgott & Jothianandan, 1991) (Figure 2.5).
Nitric oxide (NO)-mediated,
F.Ir1(14)tI1leUUm~dependentvasodilation
Figure 2.5 Nitric oxide (NO) mediated endothelium-dependent vasodilation.
Additionally, by releasing NO, the endothelium inhibits platelet and leukocyte activation,
inflammation and thrombosis while maintaining the vascular smooth muscle in a non-
proliferative state (Davignon & Ganz, 2004). Efficient endothelial function is therefore
essential in order to maintain the health of vessel walls throughout the arterial tree and NO,
in particular, is a vital component in the endogenous defence against atherosclerosis.
NO is tonically secreted by the endothelium and contributes approximately 50% to basal
vascular tone (Vallance et al., 1989). NO production can be up-regulated via physiological
stimuli such as increased flow and consequent shear stress, or pharmacologically using
receptor agonists such as acetylcholine (ACh), to induce acute arterial vasodilation.
Vasodilation is a physiological response to an acute release of NO during periods of
increased flow (Hutcheson & Griffith, 1991). Presently, the signalling cascade linking
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mechanical stimulation to the secretion of NO is incompletely understood; however,
several mechanisms are thought to be involved. Increased flow and arterial shear stress
have been reported to induce endothelial potassium channel activation (Oleson & Johnson,
1988), calcium influx in endothelial cells (Dull & Davies, 1991), release of bradykinin
(Hecker et al., 1993) and phosphorylation of serine residue (Groves et al., 1995); all of
which are thought to playa role in increasing NO bioavailability. Nonetheless, it is crucial
to acknowledge other vasoactive substances can be released by the endothelium in
response to shear stress, such as prostacyclin and endothelium-derived hyperpolarizing
factor (Grabowski et al., 1985; Kuchan & Frangos, 1993). NO readily reacts with free
radicals, and increased oxygen degradation resulting in a reduced bioavailability of NO.
This is considered a central feature of endothelial dysfunction. Thus, NO bioavailability is
commonly utilised as a surrogate marker of endothelial (dys)function.
Atherosclerosis is a progressive disease, caused by the deposition of plaques and fatty
deposits resulting in thickening of arterial walls, which precedes overt CVD. It is
characterised by vascular inflammation and infiltration of lipids, cholesterol, calcium and
cellular debris into the sub-intima of the arterial wall, resulting in vascular remodelling,
plaque formation, acute and chronic luminal obstruction and consequent blood flow
abnormalities (Stary et aI., 1995). Clinical manifestations of CVD (e.g. myocardial
infarction, angina and stroke) are increasingly apparent with age and the prevalence of risk
factors. However, the onset of the atherosclerotic disease process precedes both evidence
of traditional cardiovascular risk factors and clinical events (Chan et al., 2003). Endothelial
dysfunction is the earliest detectable event in the development of atherosclerosis that
precedes gross morphological signs and clinical symptoms (Celermajer et al., 1992; Green
et al., 2011). In the presence of endothelial dysfunction, the endothelium may adopt a
phenotype that promotes inflammation, thrombosis, vasoconstriction and atherosclerotic
lesion formation.
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2.S Measurement of Conduit Artery Endothelial Function
Non-invasive assessment of conduit artery endothelial function in vivo is commonly
utilised to assess NO-mediated vasodilator function. In the 1990's, high-frequency
ultrasonographic imaging of the brachial artery was developed to assess NO-mediated
endothelial function, using a technique called flow-mediated dilation (FMD). This method
involves direct assessment of conduit artery dilator responses to reactive hyperaemia
induced by a brief period of limb ischemia (Green et al., 2004). This stimulus causes a
shear stress that provokes the endothelium to release NO, which induces a subsequent
vasodilation (i.e. increase in arterial diameter) that can be imaged using duplex
ultrasonography (Dijkhorst-Oei et al., 1999). On the assumption that the occluding cuff,
which induces the ischemia, is positioned distal to the imaged artery (Doshi et al., 200 I)
and that the period of ischemia is not greater than five minutes (Mullen et al., 2001), the
vasomotor response of the vessel to this stimulus is largely mediated by NO (Joannides et
al., 1995; Doshi et al., 2001). The FMD response can therefore provide an index of conduit
artery endothelium-dependent NO function (Ganz & Vita, 2003).
FMD was first described by Schretzenmayr (1933), however, it was not until 1986 that the
importance of the endothelium in mediating this response was demonstrated (Pohl et al.,
1986). Pohl and colleagues (I 986) demonstrated that the femoral artery FMD response of
canines is significantly attenuated if the endothelium is denuded. A follow on study was
conducted by Sinoway et al. (1989), who first described the phenomenon of FMD in vivo
within humans, reporting a delayed dilation of the brachial artery after the time of peak
blood flow, following a reactive hyperaemic challenge. Soon after, Celermajer et al. (1992)
demonstrated that an impaired FMD is exhibited in populations with CVD risk factors.
Importantly, endothelium-derived NO was confirmed as the primary mediator of FMD in
humans by Joannides et al. (1995), who reported an attenuated FMD response in the radial
artery during the infusion of NO blocker; L-NG-monomethyl Arginine (L-NMMA). This
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finding has also been demonstrated in the brachial (Doshi et al., 2001; Mullen et al., 2001)
and femoral artery (Kooijman et al., 2008).
Doshi et al. (2001) highlighted the importance of cuff placement during the FMD
technique to ensure a NO-mediated vasodilator response. This study demonstrated that a
NO blockade almost completely abolished the vasodilator response to FMD when the cuff
was placed distal to the imaged artery (Figure 2.6). Distinct from this was the observation
that when the cuff was positioned proximally, NO blockade had much less of an effect on
the vasodilator response. Similarly, the duration of the hyperaemic stimulus is an important
factor when considering the validity ofFMD. Indeed, Mullen et al. (2001) reported that the
FMD response to transient reactive hyperaemia (5 minutes) was almost completely
abolished by NO blockade, however, following a period of sustained reactive hyperaemia
(>5 minutes) the subsequent FMD response was unaffected by NO blockade. Thus, in
order to produce a vasomotor response that accurately reflects the bioavailability of NO
and is less subject to operator bias, FMD must adhere to stringent guidelines, with any
deviation in protocol potentially increasing the contribution of alternative vasodilator
pathways (Thijssen et al., 2011).
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Figure 2.6 NO contribution to FMD using proximal and distal cuff occlusion during
control and L-NMMA infusion (Doshi et al., 2001).
2.6 Prognostic Relevance of Flow-Mediated Dilation
The observation that FMD provides a direct assessment of arterial wall function has
enthused interest in the prognostic value of the technique. Indeed, recent evidence suggests
that FMD may possess prognostic value in patients at high risk ofCVD (Green et al., 2011)
and, specifically, FMD has been reported to be an accurate independent predictor of occult
CAD (Mutlu et al., 20lla). Moreover, the independent prognostic information provided by
FMD may exceed that of traditional risk factors in clinical populations (Naghavi et al.,
2003). Takase et al. (1998) induced endothelium-dependent vasodilation in both the
coronary and brachial artery as a result of increased flow and subsequent shear stress in
response to either 20f.lg adenosine triphosphate disodium (ATP) infusion or reactive
hyperaemia. This group reported a robust relationship between coronary and brachial
artery endothelial function (r=0.79, P<O.OOl) and proposed that brachial artery FMD could
be utilised as a prognostic marker for coronary artery endothelial function (Figure 2.7). As
well as being strongly and independently associated with CVD risk and mortality in CAD
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(Takase et al., 1998; Chan et al., 2003); FMD has also been reported as an accurate
prognostic tool in CVD (Gokce et al., 2003), peripheral vascular disease (Brevetti et al.,
2003; Gokce et al., 2003) and chronic heart failure (Meyer et al., 2005a). Such studies
suggest that impaired FMD response in clinical groups is potentially indicative of future
cardiovascular events.
Figure 2.7 The relationship between flow-mediated dilation in a coronary artery stimulated
by 20llg of ATP and flow-mediated dilation in a brachial artery stimulated by hyperaemia
(Takase et al., 1998).
Interestingly, less data exist regarding the prognostic value of FMD in asymptomatic
individuals; some existing studies support the independent prognostic value of the
technique (Shechter et al., 2009) while others imply no difference in the capacity of FMD
to predict CVD risk compared to traditional risk factor assessment (Shimbo et al., 2007).
Yeboah and colleagues (2007) examined the prognostic value of FMD in an asymptomatic
aged (72-98 years) population and found FMD to be an accurate independent predictor of
cardiovascular event rate. However, the prognostic value of FMD observed in this study
only amounted to a further -1 % predictive accuracy compared with that of traditional
cardiovascular risk factors. This finding is in agreement with previous research suggesting
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that FMD may be a less accurate predictor of CVD risk in older cohorts (Witte et al., 2005).
Nevertheless, a more recent large scale multi-ethnic population-based study in 3026
younger asymptomatic participants reported that FMD added further prognostic
information regarding cardiovascular event incidence than is provided by the Framingham
risk score, when classifying patients into risk categories (Yeboah et al., 2009). Importantly,
this finding is indicative that the prognostic value of FMD may be stronger than traditional
CVD risk screening in individuals with no overt evidence of CVD. A recent meta-analysis
of 14 heterogeneous observational studies examining the relationship between brachial
artery FMD and cardiovascular events suggested that impairment of brachial artery FMD is
significantly associated with future cardiovascular events (Inaba et al., 2010). The authors
published robust risk ratios (calculated from individual studies and then pooled using
random-effects models) indicating that that the risk of a cardiovascular event increases by
21% for every 1 standard deviation (=3.5%) decrease in FMD.
FMD is traditionally considered as an index of NO-mediated vasodilator function and thus
a marker of NO bioavailability, although protocols utilised to induce an FMD response in
humans are not all equally NO dependent (Corretti et al., 2002; Green et al., 2005).
Nonetheless, a recent meta-analysis conducted by Green et al. (2011) revealed that the
FMD response to proximal cuff occlusion, which is thought to be less NO-mediated than
the response to distal cuff occlusion (Doshi et al., 2001), is in fact equally predictive of
future cardiovascular events. Whilst this does not diminish the predictive power of FMD,
these data suggest that NO may not be the sole contributor to the prognostic value of the
technique. In addition, as atherosclerosis is systemic in its development, FMD provides the
opportunity to gain insight into coronary artery health using this direct, accurate and non-
invasive technique.
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2.7 Reproductive Hormones and Conduit Artery Function
Given that peos is an endocrine disorder, primarily due to dysfunction in reproductive
hormone production, it is important to note that female reproductive hormones, namely
oestrogen, may confer some protection on the vascular system. The biosynthesis of
oestrogen is primarily influenced by FSH, which regulates the rate-limiting enzyme
aromatase that is responsible for converting oestrogens from androgens. In women with
peos, the ratio of LH (regulates androgen synthesis) to FSH is decreased due to an
accelerated hypothalamic gonadotropin-releasing hormone (GnRH) frequency (Ehrmann,
2005). As a result, aromatase activity is diminished which in tum reduces the biosynthesis
of oestrogen, and androgenic biosynthesis is up-regulated due to increased LH secretion.
Therefore, oestrogen is depleted and testosterone is elevated in women with peos
compared with non- peos women.
Williams et al. (2001) studied changes in FMD during the menstrual cycle in 15 healthy
normally menstruating women during the early follicular, late follicular, early luteal, and
late luteal phases (Figure 2.8). The authors reported that FMD was higher in the follicular
phase than the menstrual or luteal phase, which corroborates previous findings (Hashimoto
et al., 1995). It is hypothesised that this inherent variability in FMD response throughout
the course of the menstrual cycle is due to changes in oestrogen, which progressively rises
from menstruation through the follicular phase then proceeds to fall during the luteal phase
(Guyton & Hall, 1991). Herrington et al. (2001) assessed brachial artery FMD in 1636
post-menopausal women, 512 of whom were taking oestrogen replacement. There was an
association between oestrogen and improved FMD only in women who did not
demonstrate overt eVD, suggesting that oestrogen is more effective for the maintenance of
vascular health than for the treatment of established vascular disease. The influence of
oestrogen to promote vasodilation appears to be due to its ability to up-regulate eNOS
activity in the peripheral vasculature. This effect was clearly demonstrated by Hayashi et al.
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(1995) who observed increased activity of eNOS in cultured human endothelial cells
following 8 hours of oestrogen administration.
Figure 2.8 FMD of the brachial artery with reactive hyperaemia across the four phases of
the menstrual cycle. Individual data are shown together with the mean±SEM. *Significant
difference from one phase to another (P<0.05). Endothelium-independent changes in
brachial artery vasodilation did not significantly change across the four phases of the
menstrual cycle (Williams et al., 2001).
The effect of androgens on vascular reactivity is less studied than the cardioprotective
effect of oestrogen. Numerous studies have confirmed an increased prevalence of
premature atherosclerotic disease in men (Lerner & Kannel, 1986; Wingard et al., 1989);
however, there has been no consistent association between androgen levels within sex-
specific physiological ranges and cardiovascular event rates. Androgen deprivation in men
is associated with enhanced vascular reactivity (Herman et al., 1997; Empen et al., 2012)
and testosterone replacement therapy has been shown to decrease FMD of the brachial
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artery in hypogonadal men (Bernini et 01.,2006). Similarly, high dose androgen treatment
in women is associated with a reduced brachial artery FMD (McCredie et al., 1998).
However, the high dose treatment utilised in this study was in female-to-male transsexuals
and as such testosterone levels in these subjects were highly elevated (r-ISmmol/l)
compared with that observed in hyperandrogenic women with PCOS (>2.5mmoVl). The
underlying mechanism(s) relating to androgens and impaired vascular reactivity remains
unknown. In some studies, testosterone therapy has been found to decrease HDL
cholesterol (Thompson et al., 1989), however, the existing data concerning the relationship
between androgens and lipoproteins have not consistently shown detrimental effects on
endothelial function (Barrett-Connor, 1995). It is plausible that androgens impose direct
effects on the vessel wall, as steroid receptors exist in the vasculature, but this hypothesis
remains unfounded.
2.8 PCOS and Conduit Artery Function
Endothelial dysfunction, manifest as reduced FMD, has been observed in women with
PCOS when compared to control women in some (Cascella et al., 2008a), but not all,
previous studies (Beckman et al., 2007). On balance, the weight of evidence supports the
presence of endothelial dysfunction in women with PCOS and inconsistencies in the extant
literature may be related to the considerable variability between subjects or the
heterogeneity of PCOS itself, with different definitions of diagnosis, disease duration,
disease severities, and co-morbidities.
Meyer et al. (2005c) evidenced impaired endothelial dysfunction in obese and insulin
resistant women with PCOS compared with age- and BMI-matched controls and reported
that FMD was significantly correlated with both insulin resistance and fasting insulin,
which corroborated previous findings (Sorensen et al., 2006; Soyman et al., 2011).
Impaired insulin regulation is known to decrease the activation of eNOS and subsequent
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release of NG (Steinberg & Baron, 2002) suggesting that insulin resistance contributes to
endothelial dysfunction in women with PCGS. Nevertheless, several studies have reported
normal endothelial function in PCGS (Mather et al., 2000; Brinkworth et al., 2006). Arikan
et al. (2009), for example, compared brachial artery FMD and carotid artery intima media
thickness (elMT, an established structural marker for early atherosclerotic disease) in 39
healthy weight women with PCGS with evidence of insulin resistance and 30 age- and
BMI-matched controls. Despite the presence of insulin resistance determined via numerous
methods (QUICKI index, Matusda index and insulin glucose disposal AUC) there was no
difference in either FMD or clMT between PCGS or control women. Moreover, there was
no correlation between insulin resistance and FMD. There are several potential
mechanisms that could explain these differences. Firstly, the PCGS cohort utilised in the
study by Arikan et al. (2009) were -10 years younger than those in Meyer's study and
thus an effect of age or disease duration could account for inconsistencies. Secondly,
although insulin resistance was evident in both studies, hyperinsulinaemia was only
apparent in obese women with PCGS, suggesting that fasting insulin may be a more
accurate predictor of endothelial function. Thirdly, studies have utilised women with
PCGS with ranging BMI; it has been postulated that the presence of obesity in PCGS may
further increase the risk of CVD as obesity contributes to a more severe metabolic
phenotype ofPCGS (Carmina et al., 2005; Carmina et al., 2006).
Pepene et al. (2011) recorded significantly lower brachial artery FMD in women with
PCGS compared with controls although the women with PCGS in this study displayed
significantly greater BMI and total fat mass. A recent meta-analysis identified BMI as a
contributor to the risk of CHD and stroke in women with PCGS (de Groot et al., 2011),
and therefore BMI must be considered as a moderating factor on FMD in women with
PCGS. Nonetheless, it is important to note that BMI is not the most accurate marker of
obesity as it cannot distinguish between adipose and lean tissue (Oreopoulos et al., 2011).
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Women with peas demonstrate similar total and trunk fat volumes, but a higher relative
quantity of central abdominal fat (Carmina et al., 2007b) and visceral adiposity (Cascella
et al., 2008a) compared with BMI-matched controls. Cascella et al. (2008a) assessed
brachial artery FMD and VAT in 200 overweight women with peas and 100 matched
controls. The authors demonstrated impaired FMD and elevated VAT in the peas cohort
despite being matched for BMI. A significant relationship between elevated VAT and
impaired FMD response was also evident. Although this relationship has been described
previously (Hashimoto et al., 1998), this is the first study to demonstrate this relationship
in women with peas. VAT is associated with insulin resistance and adverse lipid profiles,
therefore further studies are required in order to determine the underlying mechanisms
associated with VAT that influence endothelial function in this population.
Depending on the definition utilised for diagnosis, the characterisation of peas can differ
significantly. Hyperandrogenism is a fundamental feature of 'classic' peas (Zawadzki &
Dunaif, 1992) and these patients also exhibit greater menstrual irregularity, total and
abdominal obesity, insulin resistance and demonstrate more severe risk factors for type 2
diabetes and eVD (Carmina et al., 2005; Welt et al., 2006; Carmina et al., 2009; Moran &
Teede, 2009). Although, EI-Kannishy et al. (2010a) reported significantly reduced FMD in
lean and obese women with peas, diagnosed using the Rotterdam criteria and compared
with a lean, age-matched control group. The authors reported no relationship between
FMD and insulin resistance or BMI but the data did support the role of hyperandrogenism
in vascular reactivity. Previous studies have outlined the role of sex hormones in the
maintenance of arterial health in peas (Golden et al., 2002; Westerveld et al., 2008)
although the role of androgens in relation to endothelial function remains unclear.
Interestingly, the authors described "interplay" between androgens, dyslipidaemia,
adiposity, insulin resistance and endothelial function. Further research is required in order
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to establish the specific effect these co-morbidities exert on endothelial function in women
with PCOS.
2.9 The Role of the Vascular Endothelium in Cutaneous Microvessels
Primarily, the assessment of endothelial dysfunction as a surrogate marker of CVD has
focussed on conduit vessel function. However, a growing body of evidence has emerged
suggesting that the microcirculation (network of microvessels) may be the initial site of
endothelial damage preceding structural changes and endothelial dysfunction in
macrovessels (Brodsky et al., 2004). The microcirculation is taken to include vessels
<l Sflum in diameter (De Boer et al., 2012). The skin is the largest and most accessible
organ in humans and as such cutaneous circulation has emerged as an accessible and
representative vascular bed for investigating microvascular endothelial function and
disease status (Holowatz & Kenney, 2007). Although cutaneous microvessels share
common characteristics with vessels elsewhere within the vascular tree they possess
distinct physiological and anatomical features. For example, non-acral skin plays a crucial
role in thermoregulation through which blood flow can fluctuate between near zero
(hyperthermia) to ~60% cardiac output during extreme heat stress (Kellogg, 2006).
Cutaneous microvascular function correlates with arterial endothelial function (Khan, 2008)
and several other traditional cardiovascular risk factors which frequently manifest in
women with PCOS including obesity (de Jongh et al., 2004) and hypertension (Rizzoni et
al., 2003). Systemic microvascular endothelial dysfunction is a key component in the
inherent pathogenic complications associated with diseases such as type 2 diabetes,
hypertension, CAD and hypercholesterolemia (Joann ides et al., 2006). Evidence for this
claim comes from the highly documented prevalence of microvascular complications
exhibited by type 2 diabetic patients, such as neuropathy. Thus, it is imperative to
independently assess the health and function of the microvasculature in clinical
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populations such as PCOS, in which insulin resistance and type 2 diabetes are common
pathologies.
2.10 Measurement of Cutaneous Microvessel Endothelial Function
Laser Doppler flowmetry (LDF) is a versatile technique that allows direct monitoring of
the density and velocity of blood cells within a sample volume (flux) both at rest and
during maximal provocation. As well as providing an index of maximal dilator capacity of
the skin (which is diminished with certain pathologies, see; 2.13. pcas and Cutaneous
Microvessel Function), LDF can also be used in combination with techniques such as
intradermal microdialysis to comprehensively interrogate the control of cutaneous
microvascular endothelial. function, by infusing vasoactive agonist and antagonist
substances (Figure 2.9).
Figure 2.9 The microdialysis fibre is inserted-O.3-1.0mm beneath the epidermal surface.
A 10mm semi-permeable membrane enables infusion of pharmacological agents directly
into the microvascular bed. A laser Doppler probe is positioned directly above the
experimental site to monitor cutaneous blood flow (Cracowski et al., 2006).
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2.10.1 Intradermal Microdialysis
Intradermal microdialysis is a technique that allows the continuous local delivery of potent
pharmacological agents into the epidermis (Figure 2.9) via a semi-permeable membrane,
with no systemic effect. Adapted in the mid 1990's for dermatological work, this novel
technique is the optimal method for administering L-NMMA (a NO blockade) as well as
sodium nitroprusside (SNP, a NO donor) to the interstitial space beneath the epidermal
layer (Figure 2.9). Flux over this localised area can be quantified using LDF, therefore,
changes in cutaneous blood flow induced by pharmacological stimuli can be recorded (For
details regarding the methodology of intradermal microdialysis, see Chapter 7). SNP can
be administered in conjunction with peak thermal hyperaemia to elicit maximal cutaneous
vasodilation that enables flux measures to be expressed as a percentage of a maximal
response. Maximal cutaneous vascular conductance (CVCmax) incorporates mean arterial
pressure and laser Doppler flux (CVC=laser Doppler flux/mean arterial pressure).
\
Fat, Collagen, Fibroblasts
Figure 2.10 A cross sectional diagram of human skin and "integrated microvessels.
Subcutaneous Tissue
Unlike iontophoresis, another technique to interrogate the cutaneous microvasculature,
which utilises opposing electrical currents to deliver charged pharmacological agents to
localised areas of skin is microdialysis and this method does not exhibit any confounding
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effects of electrical current-induced hyperaemia. Iontophoresis has additional well-
accepted limitations such as individual variation in the electrical resistance characteristics
of the dermal barrier, which microdialysis has been argued to overcome (Cracowski et al.,
2006). Although microdialysis is minimally invasive and only causes minor reversible
trauma, the technique is limited by the potential confounding effect of the trauma caused
during fibre insertion. Indeed, cutaneous drug delivery can be influenced by probe
insertion depth, differences in barrier functions of the skin, lag time (duration of time
before the substance enters the skin from time of administration), elimination or
metabolism rate of the delivered agent and possibly the volume of distribution (Kreilgaard,
2002). Variability can be minimised through good working practice and careful
instrumentation (minimising trauma), whereby the same researcher performs all
cannulations; ensuring a consistent cannulation depth is maintained across all participants
and time points of the study design.
2.10.2 Heat Stimulation
Particular interest has grown In the NO-mediated endothelial vasodilator function of
cutaneous microvessels, which has routinely been assessed using a heat stimulus. Studies
have consistently shown NO to be a mediator of cutaneous vasodilator responses to both
physiological (heating) and pharmacological stimuli (Kellogg et al., 1998; Shastry et aI.,
1998; Kellogg et al., 1999; Shastry et al., 2000; Minson et al., 2001; Shibasaki et al., 2002;
Holowatz et al., 2003; Kellogg et al., 2005; Stewart et al., 2007). Localised heating at
42°C has been reported to elicit the greatest contribution of NO to the vasodilator response
(-70%, (Kellogg et al., 1999; Minson et al., 2001», compared to other stimuli such as
ACh administration (-30-60%, (Boutsiouki et al., 2004; Kellogg et al., 2005; Stewart et al.,
2007») and whole body heating (-30-40%, (Shastry et al., 1998; Wilkins et al., 2003)).
Localised heating is therefore the most specific methodology currently available for the
investigation of NO-mediated cutaneous microvessel vasodilator function.
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Localised heating of the skin stimulates a temperature-dependent sustained increase in
cutaneous blood flow (Charkoudian, 2003) and achieves maximal vasodilation of
cutaneous microvessels between 42°C-44°C (Christen et al., 2004). The utilisation of a
rapid heating protocol (0.5°C increase in heater temperature every 5 seconds) has been
found to elicit a biphasic response (Minson et al., 2001) (Figure 2.11). This maximal
vasodilator response consists of an initial rapid peak in blood flow within the first 10
minutes, which has been reported to occur as a result of axon reflexes of local sensory
nerves initiating the release of known vasodilators; calcitonin gene related peptide and
substance P which elicit an increase in cutaneous blood flow. This is followed by a
secondary rise to a sustained plateau after approximately 20-30 minutes of heating (Minson,
20 10). The secondary slow rise and plateau phase of the localised heating response is
reported to be largely NO-mediated (Kellogg et al., 1998; Minson et al., 2001), with recent
evidence suggesting that NO is generated from eNOS (Kellogg et al., 2008). However,
eNOS inhibition by intradermal infusion of L-NMMA does not fully suppress the plateau
phase response to localised heating, suggesting that other vasodilators may be involved
(Minson, 2010).
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Figure 2.11 A The local heater temperature of 42°C warms the skin to -40°C which has
been shown to elicit maximal cutaneous vasodilatation. B Typical bi-phasic response to the
application of local heating, with the initial axon reflex stimulating a response -75% of the
maximal response, and the secondary plateau phase (NO-dependent) -87% of maximal
response (Minson et al., 2001).
To more thoroughly assess the cutaneous NO dilator system, a more gradual heating
protocol can be utilised that does not provoke the initial axon reflex-mediated response
(0.5°C rise every 5 minutes, Figure 2.12) (Houghton et al., 2006). Consequently, in recent
years several studies have adopted this gradual heating protocol to provide a more accurate
assessment of cutaneous microvessel NO vasodilator function (Figure 2.12). In addition,
this technique has been complimented with infusion of SNP following either peak thermal
or ACh-induced hyperaemia, (or a combination) to confirm the attainment of maximal
cutaneous vascular conductance (Figure 2.13).
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Figure 2.12 A more gradual applied heating protocol results in a smaller initial axon reflex
compared to the fast protocol utilised in Figure 2.8 (Houghton et al., 2006).
Figure 2.13 A more gradual applied heating protocol avoids provocation of the initial axon
reflex mediated response. Peak thermal-induced hyperaemia can be complimented with
infusion of SNP to confirm the attainment of maximal cutaneous vascular conductance
(Black et al., 2008b).
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2.11 Reproductive Hormones and Cutaneous Microvessel Function
Since atherosclerosis is largely limited to conduit arteries, studies have mainly focused on
the role of reproductive hormones in these vascular beds. However, there is evidence that
female hormones alter thermoregulation and thus the control of cutaneous blood flow
(Charkoudian, 2010). Previously, Charkoudian et al. (1999) examined the effect of
exogenous steroid hormones (oestrogen and progesterone), using the oral contraceptive pill,
on the cutaneous vasodilator response to local warming in young women. The authors
reported an augmented vasodilator response and hypothesised that this effect was primarily
induced by oestrogen, which is in accordance with an abundance of previous research
documenting the cardio-protective role of oestrogen on the microvascular endothelium
(Cracowski, 2011). More recently, Sokolnicki et al. (2007a) examined the effect of
oestrogen and testosterone on cutaneous microvessel dilation in response to local heating
in elderly males. All participants were simultaneously administered with a GnRH agonist,
to suppress endogenous testosterone and oestrogen production, and an aromatase inhibitor
to block the conversion of androgens to oestrogen. Thereafter, subjects were divided into
four groups whereby (a) received a testosterone gel, (b) received an oestrogen patch, (c)
received both forms of hormone replacement and (d) received no hormone replacement.
This study reported no consistent influence of either testosterone or oestrogen on cutaneous
NO-mediated vasodilation. This surprising finding was attributed to the fact that oestrogen
concentrations were relatively low in comparison to those observed in women where an
effect on vasodilation was observed. The authors concluded that the effect of testosterone
on vasodilator function remains unclear.
2.12 PCOS and Cutaneous Microvessel Function
Microvascular dysfunction can impact both vascular resistance and insulin-mediated
glucose disposal in the periphery, thereby contributing to hypertension and insulin
resistance, both of which are commonly observed in women with PCOS (Cussons et aI.,
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2006). Therefore, endothelial dysfunction in the peripheral vascular system has been
suggested as a primary mechanism for cardiovascular and metabolic risk factors commonly
observed in peos (De Boer et al., 2012). In the few studies investigating cutaneous
endothelial function in peos, cutaneous microvessel dysfunction has been observed in
response to venous occlusion plethysmography (Paradisi et al., 2001), wire myography
(Kelly et al., 2002), iontophoresis-mediated infusion of Aeh (Lakhani et al., 2005) and
microdialysis-mediated endothelin A and B agonist infusion (Wenner et al., 2011).
Paradisi et al. (2001) were the first to demonstrate endothelial dysfunction in the
microcirculation of women with peos using invasive leg plethysmography. The authors
measured leg blood flow in response to graded intrafemoral artery infusions of
methacholine chloride, an endothelium-dependent vasodilator, and to euglycemic
hyperinsulinemia in 12 obese women with peos and 13 age- and weight-matched control
women. Leg blood flow was observed to be 50% lower in women with peos compared
with matched controls following metacholine chloride infusion, and increased by only 30%
in response to euglycemic hyperinsulinemia as opposed to 60% in controls.
More recently, Lakhani et al. (2005) observed microvascular dysfunction in women with
peos compared with matched controls using iontophoresis-mediated infusion of Aeh and
SNP. The authors postulated that the abnormal response to Aeh observed may have been
due to metabolic disturbance in the peos cohort, as an impaired response to Aeh has been
demonstrated in non-insulin dependent diabetic patients (Berghoff et al., 2002). However,
some years later, Ketel et al. (2008) reported that cutaneous microvacsular function was
similar in women with peos and matched controls. Although ACh-mediated dilation is
postulated to reflect NO bioavailability, Holowatz et al. (2005) reported the contribution of
NO to this response is minimal. More recently, Wenner et al. (2011) infused endothlin A
and B agonists via the gold standard technique of intradermal microdialysis and measured
cutaneous blood flow using LDF during local heating to 42°e. Although, this study
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investigated the impact of the vasoconstrictor endothelin-l in women with peas; the
authors observed microvessel vasodilator function is compromised in women with peas.
Studies have consistently demonstrated that the NO system is a mediator of microvessel
vasodilation to a variety of stimuli (Minson et al., 2001; Holowatz et al., 2003) and that
augmented cutaneous NO-mediated mircovessel function confers anti-atherogenic
adaptation (Black et al., 2008b). The NO-mediated vasodilator pathway plays a crucial
role in the control of cutaneous endothelial function and studies that have employed the
optimal microdialysis technique (Cracowski et al., 2006) to elicit a NO blockade have
demonstrated attenuated NO function in aged (Minson et al., 2002) populations.
Nonetheless, information is currently lacking on the NO contribution to microvascular
endothelial dysfunction in women with peas.
2.13 Current Treatment Strategies for PCOS
Treatment of peas is complex as clinical manifestations vary considerably and thus
current pharmacological treatments are limited. Traditional treatment strategies in peas
target anovulatory uterine bleeding, hirsutism and acne, all of which can be managed to a
certain degree by administration of the oral contraceptive pill. Recent focus has turned to
the management of metabolic and cardiovascular complications.
2.13.1 Metformin
Presently, the pharmacological therapy metformin plays an integral role in the management
of peas. Metformin is an insulin sensitising agent and has been found to ameliorate
endothelial dysfunction in women with peas (Diamanti-Kandarakis et al., 2010).
Romualdi and colleagues (2008) observed an increased basal diameter of the brachial
artery and furthermore an increased FMD response in 13 women with peas following
three and six months of metformin therapy (1000mg/day). Nevertheless, this study
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exclusively recruited healthy weight women with peos with no evidence of insulin
resistance, therefore, these findings cannot be generalised to the peos population at large
who inherently exhibit an increased risk of type 2 diabetes (Teede et al., 2007). Diamanti-
Kandarkis et al. (2005) assessed brachial artery FMD in 20 overweight insulin-resistant
women with peos, prior to and following 6 months of metformin administration
(1700mg/day), and in 20 matched control women. The authors observed impaired FMD in
women with peos that reversed to control levels following metformin therapy. Such
studies support the hypothesis that metformin may reduce the long-term risk of
atherosclerosis and eVD in women with peos. At a molecular level metformin seems to
enhance activation of eNOS in cultured endothelial cells (Davis et al., 2006) and inhibits
oxidative stress, thereby increasing the bioavailability of NO. However, metformin
administration often results in well documented adverse side effects including nausea and
abdominal pain (Diamanti-Kandarakis et al., 20 10).
2.J 3.2 Lifestyle Interventions
As an alternative, non-pharmacological therapies, such as lifestyle modification are
advocated (Wild et al., 20 I0), and have been investigated over recent years as a
preventative strategy for eVD in women with peos. The hypothesis that type 2 diabetes
can be prevented is supported by clinical trials encompassing diet, exercise, or both in
persons at high risk for the disease (Tuomilehto et al., 2001). The largest study to
investigate the combined effect of diet and exercise was conducted by the diabetes
prevention programme research group (2002) who employed a four-year lifestyle
intervention in individuals who displayed raised fasting glucose. Participants were
randomly assigned to either placebo, metformin (850mg, twice daily) or a lifestyle-
modification programme targeting 150 minutes of physical activity per week and healthy
eating. The incidence of diabetes was 58% lower in the lifestyle intervention group and 31%
lower in the metformin group when compared to the placebo. This study clearly
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demonstrated that it is possible to delay the development of type 2 diabetes, and its
associated complications such as eAD and eVD, in the absence of pharmacological
therapy (Knowler et al., 2002).
A small randomised study demonstrated that nutritional counselling alone (n=5) compared
with nutritional counselling and exercise (n=7; 3 sessions of walking/cycling and 12
resistance exercises) each reduced fasting insulin in women with peos (Bruner et al.,
2006). Notably, there were increased benefits, evidenced by greater reductions in body fat
with exercise, although the authors could not distinguish between the effects of aerobic and
resistance exercise training. A second study examined three forms of lifestyle modification
in women with peos; diet alone, diet and aerobic exercise and diet and aerobic-resistance
exercise (Thomson et al., 2008). All three interventions successfully reduced mean body
weight, blood pressure, triglycerides, cholesterol, glucose and insulin levels, with more
favourable effects in terms of body composition observed in the exercise groups.
Specifically, there was a greater reduction in fat mass of ~45% in exercise groups.
More recently, Lass et al. (20 II) assessed the impact of a I-year lifestyle intervention on
the metabolic syndrome and eVD parameters in 59 obese adolescent peos girls (12-18y).
The lifestyle intervention was based on nutritional advice, exercise training and
behavioural therapy. In peos adolescents who achieved significant weight loss during the
intervention, cIMT, blood triglycerides, waist circumference and blood pressure improved
significantly, and the prevalence of the metabolic syndrome and homeostasis model
assessment- insulin resistance (HOMA IR) decreased; whereas no changes were observed
in peos adolescents with no weight loss. Nevertheless; the authors could not distinguish
between the effects of exercise per se from diet, behavioural therapy and/or weight loss,
nor did they include a control group for comparison.
45
2.13.3 Exercise
The androgen excess (AE)-peOS consensus statement recommends lifestyle modification,
specifically exercise, as a primary prevention strategy of eVD (Wild et al., 2010; Harrison
et aI., 2011). Despite this, a recent review of exercise intervention studies in peos
identified 8 eligible studies, only 5 of which were randomised controlled trials and only 6
examined the effect of exercise alone (without dietary restriction). Existing exercise
training studies in women with peos have reported the consistent beneficial effects of
exercise on reproductive function (Palomba et al., 2008), obesity (Moran et al., 2009b),
cardiorespiratory fitness (Vigorito et al., 2007) and insulin resistance (Hutchison et al.,
2011). Vigorito et al. (2007) observed a modest decrease in BMI and WHR in 45 women
with peos following 12 weeks of moderate-intensity cycling 3 times per week. This
reduction in obesity status was associated with a reduction in blood pressure and improved
insulin regulation. A modest exercise-induced reduction in BMI and WHR is commonly
observed within the existing literature (Giallauria et aI., 2008; Palomba et al., 2008)
although very few studies have assessed the effect of exercise on specific fat deposition. In
particular, examining the change in VAT and SAT, which are closely related to insulin
resistance (Despres, 2007), following exercise training would provide insight into the
mechanisms associated with insulin resistance and eVD in peos. Although modest
weight reduction has been reported to improve eVD risk factors in women with peos
(Pasquali et al., 1994), the effect of exercise on markers of cardiovascular risk is not
widely studied. This is surprising given the mounting evidence indicating that women with
peos are at high risk of eVD coupled with evidence indicating that exercise reduces eVD
risk in associated clinical populations including individuals with hypertension (Molmen et
aI., 2012), the metabolic syndrome (Dunkley et aI., 2012) and type 2 diabetes (Melkus,
2011).
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Hutchinson et al. (2011) examined the effect of 12 weeks intensified exercise training on
insulin resistance, using the gold standard euglycaemic clamp technique, blood profiles
and adiposity in 20 overweight women with peos. The exercise-training programme
consisted of three I-hour sessions per week which alternated between moderate-intensity
continuous (75-80% HR max) and high-intensity intermittent exercise (6x5minute bouts at
95-100% HR max). A significant decrease in VAT, blood triglycerides and insulin
resistance was observed in women with peos in the absence of significant weight loss.
This study utilised fat density estimates, also known as computer tomography, for the
assessment of fat volumes which possesses less sensitivity than MRI but provides the
accurate distinction between different fat depots (MUlier et aI., 2010). The same research
group recently administered the same exercise programme to 20 overweight and 20.obese
women with peos in order to explore the effects of exercise on glycaemic control, with
specific focus on its relationship with other cardiovascular and metabolic variables. The
authors demonstrated improvements in insulin resistance in the absence of weight loss in
both overweight and obese women with peos; although, elevated insulin resistance
remained post-exercise and there was no relationship between the change in insulin
resistance and aerobic fitness. Thus, research investigating the mechanisms accounting for
the exercise-induced improvement in glycaemic control in women with peos is warranted.
Based on the limited data available, exercise appears to exert a beneficial effect on
metabolic variables and some traditional cardiovascular risk factors in peos. However,
several studies are limited by the lack of control groups, assessments of habitual activity
and short study durations. That said, the aforementioned findings provide promising
evidence that supports the utilisation of exercise training as a treatment strategy in peos,
yet limited research exists regarding the cardiovascular effects of exercise, and its impact
on endothelial function as a predictive and prognostic marker of eVD risk has yet to be
explored.
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2.14 Exercise Training and Flow-Mediated Dilation
Endothelial dysfunction is reversible and numerous interventions that have been reported
to modify cardiovascular risk factors and reduce cardiovascular morbidity and
concomitantly, improve endothelial function (Maiorana et al., 2003). Exercise, in
particular, has been shown to improve the structure and function ofthe vascular endothelial
cells and thus offset the development of atherosclerosis (Kingwell et al., 1997a; Kingwell
et al., 1997b). Repeated bouts of exercise involve dramatic changes in haemodynamics and
resultant bouts of increased shear stress exerted on the arterial wall. It has been postulated
that this shear stress mechanism promotes the bioavailability of the anti-atherogenic
substance NO by reducing the number of oxygen free radicals and up-regulating eNOS
(Green et al., 2004). As a consequence, these exercise-induced adaptations promote
efficient vasomotor function and decrease the risk of atherosclerotic development. The
beneficial effect of exercise on endothelial dependent vasodilator function, measured using
FMD, has been demonstrated in healthy individuals (Clarkson et al., 1999) and several
diseased populations including individuals with type 2 diabetes (Maiorana et al., 2001),
obesity (Watts et al., 2004), CAD (Walsh et al., 2003) and the metabolic syndrome
(Hamdy et al., 2003). To date, no study has assessed the effect of exercise training on
endothelial function in young or post-menopausal women with PCOS.
The utilisation of exercise as a disease-management strategy, specifically in relation to
CVD risk, has been successfully employed across several high-risk populations. Walsh and
colleagues (2003) employed a randomised crossover design to compare the effect of an 8-
week circuit training programme, consisting of a combination of resistance training,
cycling and treadmill walking, with no exercise in 10 CAD patients. The authors found an
improvement in brachial artery FMD following 8 weeks of exercise training. This study
also demonstrated that lower limb exercise induces a sufficient shear stress to enhance
brachial artery (upper limb) NO vasodilator function. This is likely to be due to the
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heightened haemodynamic stress associated with exercise in large muscle groups. Exercise
training has also been reported to improve endothelial function in individuals with the
metabolic syndrome (Lavrencic et al., 2000). In this study, 29 individuals with the
metabolic syndrome were randomly assigned to either 12 weeks of high intensity cycle-
ergometry or to a control group, whereby participants maintained their habitual physical
activity levels for 12 weeks. Following the respective interventions, FMD significantly
improved in the exercise-trained group, whereas no changes were observed in the control
group. Intriguingly, the improvement in FMD occurred in the absence of any changes to
the individual components of the metabolic syndrome, indicating that exercise has a direct
therapeutic effect on the vasculature.
The beneficial effect of exercise training on FMD in heterogeneous clinical populations
demonstrating endothelial dysfunction is irrefutable. Interestingly, exercise-induced
improvements in endothelial function occur both prior to, and independent of, changes in
traditional markers of cardiovascular risk, such as BMI and blood pressure, in patients with
coronary artery disease (Walsh et al., 2003), hypertension (Higashi et al., 1999) and type 2
diabetes (Maiorana et al., 2001). At present, the underlying mechanisms that directly
mediate this exercise-induced change in heterogeneous clinical populations remain unclear.
2.15 Exercise training and NO-mediated cutaneous microvessel function
The current body of evidence relating to cutaneous vasodilator function suggests that
fitness and/or physical activity promotes increased NO bioavailability in the cutaneous
microvasculature of healthy individuals (Lenasi & Strucl, 2004; Wang, 2005). The findings
from several studies suggest that endurance exercise training can improve cutaneous
microvascular reactivity in older adults (Black et al., 2008b; Tew et al., 2010). For
example, Hodges et al. (2010) reported an increase in ACh-mediated cutaneous blood flow
following 24, 36 and 48 weeks of moderate aerobic intensity exercise in post-menopausal
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women. Surprisingly, this study also reported an increase in SNP-mediated skin blood flow
after 36 weeks of exercise training, indicative that chronic exercise may induce structural
changes to cutaneous microvessels. However, few long-term studies have been performed
and little is known regarding the effects of exercise training on cutaneous microvascular
reactivity in clinical populations and/or females.
Middlebrooke and colleagues (2006) observed no change in microvascular vasodilator
response to iontophoretically applied ACh or localised heating to 42°C in type 2 diabetic
patients following six months of aerobic exercise training. However, the exercise-training
programme in this study failed to induce an improvement in cardiorespiratory fitness,
which poses the question whether the exercise stimulus was adequate in terms of dose. In
contrast, Klonizakis and colleagues (2009) reported an augmented cutaneous vasodilator
response in response to iontophoresis-mediated infusion of ACh following eight weeks of
moderate-intensity exercise training in chronic venous disease patients. Although aged
individuals are not considered as a diseased population it is interesting that Tew et at.
(2012) found reduced cutaneous microvascular reactivity, measured using LDF, in
normotensive post-menopausal women during localised heating and post-occlusive
reactive hyperaemia. The authors then reassessed cutaneous microvessel vasodilator
function following 6, 12,24,36, and 48 weeks of endurance exercise training. The training
programme was a progressive aerobic exercise programme (30-75% HRR, 3-5 times per
week) monitored through the use of exercise diaries. Cutaneous microvessel vasodilator
function improved to similar levels of that observed in young women following 24-36
weeks of moderate-intensity aerobic exercise training. Moreover, changes in cutaneous
microvascular function correlated with improvements in cardiorespiratory fitness
suggesting that exercise is an effective management strategy to improve cutaneous
microvascular function in post-menopausal women.
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2.16 Summary
On balance, the weight of evidence suggests that conduit artery and microvessel
endothelial dysfunction, early barometers of atherosclerotic and microvascular disease, is
present in women with PCOS (Kravariti et al., 2005; Lakhani et al., 2005). Yet it remains
uncertain whether endothelial dysfunction is evident in PCOS independently, or if co-
existing morbidities are independent risk factors for endothelial function in this population.
Despite the high prevalence of CVD risk (Cussons et al., 2006), which extends into the
post-menopausal years (de Groot et al., 2011), no study to date has investigated the effects
of exercise training on conduit artery and cutaneous microvessel endothelial function in
women with PCOS.
2.17 Objectives
The aims outlined in Chapter 1will be achieved through the following objectives:
I. Conduct a systematic review of published studies relating to endothelial function
measured using the FMD technique in women with PCOS and controls, and to
quantify these findings using a formal meta-analytical approach.
2. Utilise valid and novel research techniques to assess conduit artery endothelial
function, adiposity, cardiorespiratory fitness and blood profiles in PCOS and
matched control women.
3. Examine the relationship between conduit artery endothelial function and potential
moderators, such as adipose tissue volumes and insulin resistance, in women with
PCOS.
4. Engage women with PCOS in either a 16-week supervised moderate-intensity
aerobic exercise training programme or a 16-week period of conventional care
(following general lifestyle advice).
5. Compare the effect of exercise and conventional care on conduit artery endothelial
function adiposity, cardiorespiratory fitness and blood profiles.
6. Utilise intradermal microdialysis to directly interrogate NO-mediated cutaneous
microvessel vasodilatation in response to gradual heating in PCOS and matched
control women.
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7. Engage women with peos in a 16-week supervised moderate-intensity aerobic
exercise training programme to assess the effect of exercise on NO-mediated
cutaneous microvesseI vasodilator function.
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CHAPTER3
ENDOTHELIAL FUNCTION MEASURED USING
FLOW MEDIATED DILATION IN POLYCYSTIC
OVARIAN SYNDROME: A META-ANALYSIS OF
THE OBSERVATIONAL STUDIES
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3.1 Introduction
Polycystic Ovarian Syndrome (peOS) is the most common endocrinopathy in females of
reproductive age, with a prevalence of up to 20% when utilising the more liberal
Rotterdam criteria (Goodarzi et al., 2011). peos is characterised by hyperandrogenism,
menstrual dysfunction secondary to anovulation and polycystic appearance of the ovaries
upon trans-vaginal ultrasound assessment (Goodarzi et al., 2011). This can be identified
using three consensus definitions; National Institute of Health (NIH) guidelines (Zawadzki
& Dunaif, 1992) and the Androgen Excess Society (AES) consensus, both of which
classify peos primarily as a hyperandrogenic disorder, or the broader Rotterdam criteria
(2004). Importantly, it has been suggested that women with peos are at greater risk of
cardiovascular disease (eVD) and type 2 diabetes. Despite epidemiological evidence
suggesting an increased cardiovascular morbidity and coronary artery mortality in women
with peos, study findings are equivocal (Wild et al., 2000; Schmidt et al., 2011) and little
data are available regarding cardiovascular outcomes (Wild et al., 2000). It is possible that
the increased cardiovascular risk could be related to the presence of a number of risk
factors evident in women with peos such as abdominal obesity, insulin resistance,
dyslipidemia and hypertension (Pierpoint et al., 1998). It is yet to be established whether
peos per se and/or the presence of associated cardiovascular risk factors translates into
increased eVD.
Several risk factors, evident in women with peos, are associated with endothelial
dysfunction. Endothelial dysfunction is an important early event in the development of
atherosclerosis, which precedes gross morphological signs and clinical symptoms. Non-
invasive assessment of endothelial function in vivo is commonly undertaken using the
FMD technique (Thijssen et aI., 2011). This method involves direct assessment of conduit
artery dilator responses to reactive hyperaemia induced by a brief period of limb ischaemia
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via an occluding cuff placed immediately proximal or distal to the imaged site (Green et al.,
2004). The prognostic value of FMD assessment is well established in patients exhibiting
an increased risk of CVl) (Green et al., 2011) and, specifically, FMD has been found to be
an accurate independent predictor of occult coronary artery disease (MutIu et al., 20 11b).
Indeed, the independent prognostic information provided via FMD may exceed that of
traditional risk factors in clinical groups (Naghavi et al., 2003). Endothelial dysfunction,
manifest as reduced FMD, has been observed in women with peos when compared to
control women in some (Cascella et al., 2008b), but not all previous studies (Beckman et
al., 2007). Even when women with peos were compared with age and BMI matched
controls Soares et al. (Soares et al., 2009) found no significant difference in FMD, a
finding that is consistent with previous studies (Arikan et al., 2009; Moran et al., 2009a).
In contrast, Meyer et al. (Meyer et al., 2005c) and El-Kannishy et al. (El-Kannishy et al.,
20 1Ob), demonstrated differences in early functional markers of arterial disease, including
FMD, in women with peos compared to a matched control group. This disparity in the
extant literature may be related to different methods employed to assess FMD, the
considerable variability between subjects, with different definitions of diagnosis, disease
duration, disease severities, and co-morbidities or to poorly matched control groups.
Therefore, the aim of this study was to systematically review the literature relating to
endothelial function, measured using the FMD technique, in peos, to obtain a more
precise estimate of whether a peOS-related impairment in FMD exists; and to explore the
influence of potential between-study moderators such as age and obesity status on the
difference in FMD between peos and control women. We also aimed to elucidate whether
the different diagnostic criteria for peos influences FMD, which is to date an unexplored
moderator.
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3.2 Methods
3.2.1 Data Source
A systematic review of peer-reviewed studies was undertaken comparing endothelial
function, quantified by means of FMD, in peos compared with control women. This
literature search was conducted using the Pubmed, BIOSIS, Scopus, eINAHL and
WebofScience scholarly databases (2000-2011). Key search words included Polycystic
Ovarian Syndrome, vascular function/dysfunction, endothelial function/dysfunction and
flow mediated dilatation. Reference lists of relevant published works selected were also
examined in order to identify additional pertinent studies.
3.2.2 Study Selection
Two members of the research team (VSS and HJ) independently selected the studies for
inclusion in the meta-analysis and later met to reach a mutual consensus. Twenty-one
studies met the initial inclusion criteria, described below, and were incorporated into phase
1 of the analysis. Subsequently, a sub-set of these studies was created by implementing a
more stringent inclusion criterion to form phase 2 of our analysis. Specifically, for phase 2
of the analysis, studies were selected that recruited women with peos using the Rotterdam
criteria (2004) as only one study that met our initial inclusion criteria utilised the AES
(Azziz et al., 2006) criteria and only five recruited using NIH guidelines (Zawadzki &
Dunaif, 1992).
3.2.3 Criteria for Phase 1Analysis
Published literature relating to endothelial function, assessed via FMD of the brachial
artery, in peos and non-Pf'OS women was compiled. In order to minimise measurement
error studies were selected based on the utilisation of an analysis technique whereby either
an average is derived from multiple diameter measurements determined along a segment of
the vessel or the use of automatic edge detection software; and the stimulus to induce
56
hyperaemia was for 4-5 mm m duration. This criterion was devised based upon
recommendations from technical guidelines on FMD measurement to minimise variability
between studies (Corretti et aI., 2002; Thijssen et aI., 2011). All studies reported relative
FMD (% change from baseline to peak diameter). Studies that recruited women with peos
via various diagnostic definitions including; Rotterdam (2004), NIH (Zawadzki & Dunaif,
1992) and AES (Azziz et aI., 2006) were considered. We also incorporated studies that
included smokers. Twenty-one studies were identified during this process (Figure 3.1); at
whole study level demographics for women with peos ranged from 22-34yrs and 21-
37kg/m2 and for control women were from 23-41yrs and BMI range was 27-37kg/m2
(peOS n=908; control participants n=566). The selected studies excluded individuals
based on current use or use within the last three months of insulin-sensitising agents
(metformin and/or pioglitazone), weight loss medication, anti-androgens, fertility
treatments, glucocorticoids or medication which could alter vascular function such as the
oral contraceptive pill.
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594 potentially relevant studies
were identified
551 excluded on basis
of title and abstract
Comprehensive assessment against
inclusion and exclusion criteria by
first and last author
35 excluded due to
incomplete data.
previously presented
data. duplicates and
I Phase} I exclusion criteria
21 studies matched initial inclwion
criteria but involved different
methods of diagnosis. smoking
status and matching
I Phase2 I
7 studies with strictlyhomogenous
characteristicswerealso meta-
analysed
Figure 3.1 Summary of study assessment and exclusion stages.
3.2.4 Criteria/or Phase 2 Analysis
Reviewers selected studies that; I) specifically recruited peos via the Rotterdam criteria;
2) matched peos and control women for age and BMI; 3) recruited participants over 18
years of age; 4) assessed endothelial function in the brachial artery via the FMO technique;
5) excluded smokers; 6) reported only previously unpublished data. Eight published studies
were identified during this procedure. One of these studies (Arikan et aI., 2009) reported
sample mean values of FMO for peos and controls of approximately 23-25%. The values
were approximately three times higher than the average for the other seven studies. The
associated SOs reported in the manuscript by Arikan et al. (Arikan et aI., 2009) indicated
that some FMO measurements were higher than 45%, which is unfeasibly large. Therefore
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this study was removed from analysis. The pathway of systematic reviewing is presented in
Figure l.The PCDS demographics in this phase ranged from 23-31yrs and 21-29kg/m2 and
control demographics ranged from 23-34yrs and 21-29kg/m2 (PCDS n=441; control
participants n=281). All PCDS and control women were normotensive and not taking any
medication.
3.2.5 Statistical Analyses
Version 2 of the Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ)
was utilised to conduct a random-effects (DerSimonian-Laird inverse variance approach)
meta-analysis of the mean difference in FMD between PCDS and control women, at whole
study level (DerSimonian & Laird, 1986). All studies included in the analyses comprised
of two independent groups. Relative weights were assigned to each study mean difference
on the basis of respective standard errors. Study cohorts were coded for smoking status (as
includes smokers or excludes smokers, studies that did not specify about smoking were
coded as includes smokers) and for cuff placement (distal or proximal). Mean age and BMI
were included as moderating variables in Phase 2. All data are presented as mean (95%
confidence intervals).
The primary outcome variable in all of the relevant studies was FMD (%). We found that
the sample means of FMD% generally followed a normal distribution. The correlation
coefficient between the sample mean diffemeces in FMD and the respective standard
errors was found to be 0.2, indicating the absence of substantial heteroscedasticity. Besides,
we also analysed the data as standardised effect sizes which should also control for any
heteroscedasticity (see below). Across all selected studies (phase 1) the average number of
women with PCDS was 45 and the average number of control women was 27. Studies
were grouped by cuff placement and smoking status to examine the effect of these,
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potentially confounding, variables. For phase 2 the mean number of women with peas
was 55 and the mean number of control women was 35.
3.2.6 Exploration of heterogeneity
Exploration of heterogeneity was examined only in the phase 2 analyses, since specific
sources of heterogeneity from inclusion/exclusion criteria were already known to be
present in the phase 1 analysis, and then these were removed for the phase 2 analyses.
Heterogeneity was explored with the Q-test and I-square statistic, which quantifies that
variation that is due to heterogeneity rather than sampling error (chance) (Higgins et al.,
2003). A Q statistic was deemed significant when P<0.05. An I-square statistic >50% is
deemed to be indicative of substantial heterogeneity. Such information can be used to
inform the appropriateness of the choices of a random effects analysis and moderator
influence, e.g. via meta-regression approaches. In the event of substantial heterogeneity
still being present in phase 2, we performed the following sensitivity analyses; a meta-
analysis of the standardised mean differences between peas and controls as well as re-
analyses with outlier studies removed.
3.2.7 Meta-regression analyses of potential moderators of FMD difference between
samples
The study differences in FMD between peas and control women were meta-regressed
against mean study age and mean study BMI. The study differences in FMD were also
compared between studies based on the smoking status of the participants (all non-smokers
vs smokers and non-smokers studied together as one sample).
3.2.8 Exploration of Publication Bias
The presence of publication bias was explored with observation of a standard funnel plot of
PeGS-control difference vs. study standard error, and quantatively via Egger's linear
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regression test (Egger et al., 1997). If this test is statistically significant, it indicates that
there may be a bias of small sample studies which report no significant difference in FMD
between peos and controls having not been submitted and/or accepted for publication.
3.2.9 Quality Assessment
A systematic appraisal of quality for observational research (SAQOR) was devised,
specifically for this analysis, by the research team in order to provide a minimal qualitative
assessment of study quality. The SAQOR was adapted from existing quality assessment
tools (Ross et al., 2011) and adjusted to assess i) the peos sample, ii) the control group, iii)
quality of measurement, iv) confounding variables and v) data. Overall, the SAQOR was
scored out of 14, quality is deemed better with a greater score.
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3.3 Results
3.3.1 Phase 1
The pooled mean values ofFMD were 8.7% (6.7-10.7) and 12.1% (9.8-14.4) for the rcos
and control samples respectively. The pooled mean FMD was found to be 3.4% (95%
Cl=l.S, 4.9) lower in women with peos compared with control women (P<O.OOI, Figure
3.2). There was evidence of statistically significant and substantial heterogeneity between
studies (Q2o=445.6, P<O.OOI; 12=96%). When this meta-analysis was repeated with the
standardised difference in FMD as the outcome, the pooled mean standardised reduction in
FMD was found to be 0.93 (0.51-1.35), but heterogeneity was still high (I-square = 91%).
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Figure 3.2 Forest plot demonstrating the individual study difference in mean FMD (%)
between peos and control women (and associated 95% confidence interval) in our Phase
1 analysis. Also shown (in the final row is the random-effects estimate of the pooled mean
difference in FMD between peos and controls.
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3.3.2 Phase 2
The pooled mean values ofFMD were 8.4% (4.3-12.2) and 12.5% (8.4-16.6) for the peos
and control samples respectively. The meta-analysed pooled reduction in FMD was found
to be 4.1% (95% eI=2.7, 5.5) in women with peos diagnosed via the Rotterdam criteria
when compared with control women (P<O.OOI, Figure 3.3). There was evidence of
statistically significant and substantial heterogeneity between studies in this phase 2
analysis with stricter quality criteria, although the e value was lower than that obtained in
the Phase 1analysis on the larger more heterogeneous sample of studies (12=81%). The
mean difference in FMD between peos and control women was not influenced by BMI
(P=0.17) or age (P=0.38). As well as being non-significant, the slope of regression for
BMI was very shallow with the group difference in mean FMD changing by only 0.13%
for every 1 kg/rrr' increase in BMI. Egger's regression intercept revealed that there was no
evidence of publication bias (lntercept=-0.22, 95% eI=-3.5, 3.12, P=0.90).
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Figure 3.3 Forest plot demonstrating the individual study difference in mean FMD (%)
between peos and control women (and associated 95% confidence interval) in our Phase
2 analysis. Also shown (in the final row in bold text) is the random-effects estimate of the
pooled mean difference in FMD between peos and controls.
3.4 Discussion
This two-phase meta-analysis encompassing 21 studies with 908 peos and 281 control
women provides compelling evidence that brachial artery FMD, a strong and independent
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predictor of future cardiovascular events is impaired in peos. This analysis supports
previous evidence suggesting peos per se infers greater eVD risk but, importantly, also
provides information regarding the extent of eVD risk in this population. The authors of a
recently-published meta-analysis on the prognostic value of FMD reported that the risk of
a cardiovascular event increases by 21% for every 1 standard deviation decrease in FMD
(Inaba et al., 2010). This effect size corresponds to an approximate 21% increase in risk for
every 3.5% decrease in FMD. Although this previous meta-analysis did not specifically
involve peos patients, it is interesting to note that we observed a mean FMD reduction of
3.4-4.1% in peos compared with controls women, suggesting that the risk of
cardiovascular events is higher in women with peos.
To our knowledge this is the first meta-analysis investigating the impact of peos on FMD,
a sub-clinical marker of eVD risk. Previous systematic reviews and meta-analysis studies
are suggestive of increased eVD risk in peos. Our data corroborate this notion, and
provide information that enables comparison of risk ratio's for future cardiovascular events.
Another novel aspect of this study is that we have employed a two-staged approach to
examine the intricacies of the peos diagnostic criteria and the impact of BMI and age on
the level of FMD impairment in peos. We observed that FMDwas consistently impaired
in women with peos independent of diagnostic criteria. Likewise, in phase 2 of our
analysis, which controlled for the effect of age and BMI, a significant impairment in FMD
in women with peos remained.
One advantage of this study is that we employed meta-regression analysis to examine the
impact of moderating variables on the difference in FMD.Age was not a moderating factor
on the difference in FMD response between peos and control women, but this could be
due to the small age range between participants (23-31years). We found that BMI did not
influence the difference in FMD between peos and control women with a 0.13% change
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in FMD for every lkg/rrr' increase in BM!. Intriguingly, when the PCOS and control
groups were matched for BMI and only diagnosed using the Rotterdam criteria FMD was
impaired in lean women with PCOS as well as overweight and obese women. Although,
women diagnosed via the Rotterdam criteria, as illustrated in our analysis, generally
exhibit a lower BMI compared to those diagnosed using the 'classical' NIH criteria
(Zawadzki & Dunaif, 1992), for which hyperandrogenism is a fundamental diagnostic
feature and is associated with increased obesity (Carmina et aI., 2005). Our data may
therefore suggest that impaired FMD is an inherent attribute in PCOS and advocates the
notion that FMD might be a useful prognostic tool for CVD in this population.
Given that BMI was the only consistently reported marker of obesity within the studies
included in the present meta-analysis we cannot currently make firm conclusions about the
impact of obesity on endothelial dysfunction in women with PCOS. We are aware that
BMI cannot distinguish between adipose and lean tissue (Oreopoulos et al., 2011) and
central abdominal fat, which is greater in women with PCOS (Carmina et al., 2007a),
would have provided a more robust marker of adiposity, which is strongly associated with
an increased risk of atherosclerosis (Gasteyger & Tremblay, 2002) and CVD mortality
(Dagenais et aI., 2005). We also acknowledge visceral adipose tissue (VAT) may influence
FMD in women with PCOS. Caescella et al. (Cascella et aI., 2008a) reported an
association between VAT thickness, measured using ultrasound, and impaired FMD in
women with PCOS. Furthermore, excess VAT accumulation is responsible for the up
regulation of p oxidation which subsequently results in oxidative stress, the release of
inflammatory cytokines and adipokines and a reduction of endogenous adiponectin, an
anti-inflammatory substance (Carmina et al., 2006; Cascella et al., 2008b; Carmina et aI.,
2009; Pepene, 2012) all of which could contribute to endothelial dysfunction. Therefore,
further investigation of endothelial function related to specific fat deposition in women
with PCOS is warranted.
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The fundamental aim of this meta-analysis was to obtain a more precise estimate of the
PCOS-related impairment in FMD using a large number of previous studies to enhance
statistical power and precision. A notable strength of this study is the utilisation of meta-
regression analysis to explore the influence of the important between-study moderators of
age and BMI between PCOS and control women. Nevertheless, the data reported in this
study should be interpreted in line with its limitations. The measurement of FMD is
traditionally considered as an index of NO-mediated vasodilator function and thus is a
surrogate marker of CVD risk. Since its inception in 1992, FMD has become the most
commonly used non-invasive assessment of vascular endothelial function in humans.
Advances over the last decade have resulted in a refined understanding of the physiology,
analysis, and interpretation of this technique (Harris et al., 2010). Although we are aware
of several techniques, which exist for the assessment of endothelial function and other
surrogate markers of CVD risk, the primary aim of the study was to focus on the FMD
technique. Additionally, not all studies employed a published consensus definition for the
diagnosis of PCOS; studies investigating endothelial function to discern between the
different phenotypes of PCOS and their associated risk are clearly warranted. We
acknowledge that a multitude of factors are exhibited in women with PCOS that could
potentially influence FMD, most notably, hyperandrogenism and insulin resistance. Yet,
we were unable to include these variables as moderators since a large number of previous
studies either did not measure and/or report such data (e.g. waist circumference) or the
studies utilised a wide variety of techniques to measure a variables (e.g. insulin resistance,
measured via HOMA-IR, QUICKI, MATSUDA, AUCg-AUCi ratio).
Our primary outcome was the percentage change in diameter from a resting baseline to a
hyperaemic peak value. This approach to expressing change in diameter is ubiquitous
across studies, which enabled the meta-analysis to be undertaken, yet this approach might
not be the most appropriate. Percentage change and ratio statistics have been criticised in
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many research contexts, since they may not scale consistently over the full range of
diameter sizes (Packard & Boardman, 2008). There are other approaches to expressing
change while controlling for general anatomical size, involving analysis of covariance and
allometric techniques. Unfortunately, these approaches have only been applied to a few
recent FMD studies (Birk et al., 2012).
In summary, this meta-analysis suggests that endothelial dysfunction is inherent in women
with peos, even if they are young and non-obese. Therefore, our in-depth analysis infers
that women with peos are at greater risk of eVD. Importantly, this FMD impairment and
associated eVD risk was not explained by the diagnostic criteria but may be affected by
differences in adiposity in terms of fat deposition and/or distribution.
69
CHAPTER4
GENERAL METHODS
70
Many of the methods undertaken in this thesis were adopted throughout Chapters 5-7. The
specific protocols employed for each study can be found within the respective method
sections for each chapter.
4.1 Participants
Women with PCOS were recruited from the gynaecology and reproductive medicine clinic
at Liverpool Women's Hospital, Liverpool, UK. PCOS was diagnosed by means of the
Rotterdam criteria for diagnosing PCOS (2004), based on the presence of two of the
following three criteria; i) clinical (acnelhirsutism) or biochemical hyperandrogenism
(testosterone> 2.Smmol/l), ii) oligomenorrhoea or amennorhoea, iii) polycystic appearance
of the ovaries upon ultrasound (enlarged ovarian volume> 1Ocm3or > 12 follicles between
2-9mm in diameter), having excluded other possible causes by appropriate biochemical
tests. Control participants were recruited via local advertisement. Only sedentary
individuals were recruited «2 hours of weekly exercise based on a self-reported
questionnaire). All participants were over 18 years of age and had no history of type 2
diabetes, cardiovascular, liver, kidney or respiratory disease and displayed no contra-
indications to exercise. Current use or use within the last three months of insulin-
sensitising agents (metformin and/or pioglitazone), orlistat, anti-androgens, fertility
treatments, glucocorticoids or medication which could alter vascular structure and/or
function such as the oral contraceptive pill resulted in exclusion. All participants were non-
smokers and drank <14 units of alcohol per week. In control women, data was collected
during the early follicular phase of their menstrual cycle, and confirmed using reproductive
hormone profiles. This was not feasible in women with PCOS, due to the erratic nature of
their cycles. Participants were asked to fast for 12 hours, abstain from alcohol and caffeine
for 24 hours and refrain from exercise for 48 hours prior to testing sessions. The study
conformed to the Declaration of Helsinki and was approved by the local research ethics
committee (LREC). All participants were informed of the methods verbally and in writing
71
before providing written informed consent.
4.2 Anthropometric Measurements
Height was measured in a freestanding position to the nearest 0.5 cm using a measuring
device (Seca, Model 220, Germany). Body mass was measured to the nearest 0.05 kg using
calibrated electronic digital scales (Seca, Model 767, Germany). From this, body mass
index (BMI; mass (Kg) I (height (mr') was calculated. Waist and hip circumference was
measured at the level of the umbilicus and greater trochanter, in duplicate, and waist: hip
ratio (WHR; waist circumference (cm) I hip circumference (cm)) calculated. Resting blood
pressure (mm Hg) and resting heart rate (beats/min) were also determined from an average
of three measures using an automated BP monitor (Dinamap, G & E Medical, Tampa,
Florida).
4.3 Biochemical Assays and Evaluation
Following an overnight fast, blood was drawn for biochemical profile, including total
cholesterol, triglycerides, high-density (HDL) and low-density (LDL) lipoprotein
cholesterol, alanine aminotransferase (ALT), glucose and insulin. Circulating reproductive
hormone levels were measured including follicle stimulating hormone (FSH), luteinizing
hormone (LH), oestradiol, progesterone, testosterone and sex hormone binding globulin
(SHBG).
Total cholesterol, HDL, LDL, triglycerides, glucose and ALT were measured using
standardised assays (Olympus A2700). LH, FSH, oestradiol, progesterone, total
testosterone and SHBG concentrations were measured by a chemiluminescence method
(Siemens Centaur). Free androgen index (FAI) was calculated as 100 x [testosterone
concentration (nmol/l)/SHBG concentration (nmol/l)] (normal<7%) (Mathur et al., 1981).
Insulin was measured using an ELISA kit (Invitrogen, UK). Using fasting baseline glucose
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and insulin concentrations, insulin resistance was calculated by the homeostasis model
assessment for insulin resistance (HOMA-IR) (Matthews et al., 1985). Blood samples were
analysed by an experienced laboratory technician.
4.4 Vascular Function
All vascular function assessments were performed in a quiet, temperature-controlled
laboratory. Upon arrival, participants rested in the supine position for -20 minutes to
facilitate assessment of baseline mean arterial pressure (MAP) and heart rate (HR).
Following the rest period, HR and MAP were determined from an average of three
measures on the left arm. Participants were then positioned with their right arm extended
and immobilised with foam supports at an angle of -800 from the torso.
4.4.1 Brachial Artery Flow-Mediated Dilatation
A 10-MHz multi frequency linear array probe attached to a high resolution ultrasound
machine (Siemens Medical Solutions, USA) was utilised to image the brachial artery in the
distal one third of the upper right arm. When an optimal image was acquired, the probe
was held stable and the ultrasound parameters were set to optimise the longitudinal, B-
mode images of the lumen-arterial wall interface. Continuous Doppler velocity assessment
was also obtained using the high resolution ultrasound machine and was collected using a
600 isonation angle. Nitric oxide (NO) mediated endothelial function was assessed by
measuring flow-mediated dilation (FMD) in response to a 5 minute ischaemic stimulus,
induced by forearm cuff inflation (Thijssen et al., 2011). Baseline images were recorded
using specialised recording software (Camtasia). A rapid inflation and deflation pneumatic
device (D.E. Hokanson, Bellevue, WA) was used with an inflation cuff placed immediately
distal to the olecranon process on the forearm of the imaged arm to provide a stimulus for
forearm ischemia (Corretti etal., 2002). A baseline recording lasting I minute was
acquired before the forearm cuffwas inflated (-220 mmHg) for 5 minutes. Artery diameter
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and blood flow velocity recordings were resumed 30 seconds prior to cuff deflation and
continued for 3 minutes thereafter (Black et al., 2008a). Peak brachial artery diameter and
blood flow velocity, and the time taken to reach these peaks following cuff release were
recorded.
4.4.2 Brachial Artery Endothelium-Independent Vasodilation
Following a ~15 minute rest period, a 1 minute baseline recording of the brachial artery
was acquired. Subsequently, brachial artery endothelium-independent vasodilation was
examined following administration of sublingual glyceryl tri-nitrate (GTN, 400fJg), a NO
donor. GTN provides an endothelial-independent source of NO with which it challenges
the integrity of the smooth muscle and thereby provides an insight of smooth muscle
sensitivity and a subsequent short-term increase in blood flow velocity and arterial
diameter. The brachial artery was imaged for 10-min following administration of GTN.
4.4.3 Brachial artery diameter and bloodflow velocity analysis
Analysis of brachial artery diameter was achieved using custom-designed edge-detection
wall tracking software, which is largely independent of investigator bias (Woodman et al.,
200 I). The image was taken directly from the ultrasound machine and saved as an AVI file.
Subsequent software analysis of this data was performed at 30Hz using an icon-based
graphical programming language and toolkit (LabVIEW 6.02, National Instruments). The
initial phase of image analysis involved the identification of regions of interest (ROI) on
the first frame of every individual study. These ROI's allowed automated calibration for
arterial diameter on the B-mode image (Figure 4.1) and velocities (Figure 4.2) on the
Doppler strip. A ROI was then drawn around the optimal area of the B-mode image and
within this ROI a pixel-density algorithm automatically identified the angle-corrected near
and far-wall e-lines for every pixel column within the ROI. The algorithm begins by
dividing the ROI into an upper half, containing the near wall lumen-intima interface, and a
74
lower half containing the far wall interfaces. The near-wall intimal edge is identified by a
Rake routine that scans from the bottom to the top of the upper half of the ROI. The
position of the edge is established determining the point where the pixel intensity changes
most rapidly. Therefore, typical B-mode ROI's contained approximately 200-300 diameter
measures per frame, the average of which was calculated and stored. This process
transpired at 30 frames per second. A final ROI was drawn around the Doppler waveform
and automatically identified the peak of the waveform. The mean diameter measures
derived from within the B-mode ROI were then synchronised with the velocity measure
derived from the Doppler ROI at 30 Hz. Ultimately, from this synchronised diameter and
velocity data, blood flow (the product of lumen cross-sectional area and Doppler velocity
and shear rate (4 times velocity divided by diameter) were calculated at 30 Hz (Black et al.,
2008a).
All data were written to file and retrieved for analysis in a custom-designed analysis
package. It has been previously demonstrated that reproducibility of diameter
measurements using this semi-automated software is significantly better than other manual
methods, significantly reduces observer error, and possesses an intra-observer CV of 6.7%
(Woodman et al., 2001). Furthermore, our method of blood flow assessment is closely
correlated with actual flow through a "phantom" arterial flow system (Green et al., 2002).
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Figure 4.1 2D B-Mode Ultrasound image recording of the brachial artery in the analysis
software with ROl highlighted.
Figure 4.2 Blood flow velocity trace.
4.4.4 Vascular Data Analysis
Baseline diameter, flow, and shear rate were calculated as the mean of data acquired across
the I-minute baseline period preceding cuff inflation. Peak diameter following cuff
deflation was automatically detected according to an algorithm that identified the
maximum bracket of data subsequent to performance of a moving window smoothing
function. This smoothing routine calculates the median value from 100 consecutive
samples before the window shifts to the next bracket of data, which shares 20% overlap
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with the preceding bracket. The maximum value of all the calculated median values is then
automatically detected and chosen to represent the peak of the post-deflation artery
diameter curve. FMD was calculated as the percentage rise of this peak diameter from the
preceding baseline diameter. The time to peak diameter (in seconds) was calculated from
the point of cuff deflation to the maximum post-deflation diameter. Calculation of FMD
and time to peak were therefore observer-independent and based on standardised
algorithms applied to data that had undergone automated edge-detection and wall-tracking
analysis.
In accordance with recent findings (Pyke & Tschakovsky, 2007), we calculated the shear
rate stimulus responsible for endothelium-dependent FMD. The post-deflation shear rate
data, derived from simultaneously acquired velocity and diameter measures at 30 Hz, was
exported to a spread sheet and the area under the shear rate curve (AUC) calculated for
data up to the point of maximal post-deflation diameter (FMD) for each individual using
the trapezoid rule.
4.5 Magnetic Resonance Methodology
All women underwent magnetic resonance imaging (MRI) scanning in a 1.5T Siemens
Symphony scanner (Siemens Medical Solutions, Erlangen, Germany) in a prone position,
being moved through the magnet to acquire full body coverage. Scans were anonymised
prior to analysis thus ensuring the observer was blinded to all clinical details.
3.5.1 Volumetric analysis of adipose tissue content
Total Internal (lAT) and subcutaneous adipose tissue (SAT, fat located immediately below
the dermal layer) as well as abdominal SAT and visceral adipose tissue (VAT, fat depots
surrounding the internal organs of the abdomen) were calculated from whole body axial
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Tl-weighted fast spin echo scans (axial scans, 10rnm slice thickness followed by a lOmm
gap using the integral body coil). The abdominal region was defined as the image slices
from the slice containing the femoral heads, to the slice containing the top of the liver/base
of the lungs (Figure 4.3). All scans were analysed centrally, and anonymised prior to
analysis ensuring blindness to all clinical details.
Figure 4.3 One trans-axial image of abdomen. Area highlighted in green represent
abdominal subcutaneous fat and area highlight in red represent abdominal visceral fat.
4.5.2 Proton magnetic resonance spectroscopy (IH-MRS)
Three voxels of interest were identified in the liver at standard sites avoiding ducts and
vasculature (Figure 4.4). In skeletal muscle a single voxel was identified in each of the
tibialis anterior and soleus muscles, avoiding bone, fascia and the neurovascular bundle
(Figure 4.5). Single voxel spectroscopy was conducted at each of these five sites. Voxel
size was 20x20x20mm, TE 135ms, TR 1500ms, with 64 acquisitions. Where the muscle
was too small to allow placement of a 20mtn voxel, a 15x 15x20mm voxel was placed and
the number of acquisitions was increased to 200 to maintain signal-to-noise ratio. lHMR
spectra were quantified using the AMARES algorithm in the software package jMRUI-3.0
(Vanhamme et al., 1997; Naressi et al., 2001). As previously described, liver fat is
expressed as % of CH2 lipid signal amplitude relative to water signal amplitude after
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correcting for TJ and T2 (Thomas et al., 2005), and intramyocellular lipid (IMCL) is
expressed as CH2 lipid amplitude relative to total creatine amplitude after correcting for T J
and T2 (Figure 4.6) (Rico-Sanz et al., 1999).
Figure 4.4 Example of the voxel positions used during liver spectroscopy.
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Figure 4.5 Example of the voxel positions used during tibialis anterior and soleus
spectroscopy.
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Figure 4.6 Percentage ratio of the CH2 lipid peak area relative to the water peak area.
4.5.3 Reproducibility of MRI and MRS analysis
Volumetric analysis of adipose tissue content: The mean coefficient of variations (CoV)
were determined as total body fat, 1-2%; total subcutaneous fat, 3-4%; abdominal
subcutaneous fat, 1-3%; visceral fat, 6-8%.
Examination of liver fat (IHCL Cllvwater): The mean inter-examination CoY for using
this protocol was found to be 7.0% (range 4.0-11.7%) and the mean intra-examination
CoY was significantly lower (6.0%) (Thomas et al., 2005).
4.6 Maximal Oxygen Consumption Test
Each subject performed a fitness test (V02peak) to quantify their aerobic capacity. This
comprised of a 2-minute warm up followed by an incremental exercise to volitional
exhaustion performed on a treadmill ergometer (H/PI Cosmos, Pulsar 4.0, Nussdorf-
Traunstein, Germany) in a temperature-controlled environment (Bruce et aI., 1973).
Following a 2-minute warm up at 2.2km/h on a flat gradient, the initial workload was set at
2.7km/h at 5° grade. Thereafter, step-wise increments in speed and grade were employed
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every minute. Heart rate was continuously measured (Polar Electro Oy, Finland) and the
participant's perception of effort was monitored using the BORG scale (Burkhalter, 1996;
Borg, 1998).
V02peak during exercise was calculated from minute ventilation, measured using a
pneumotach and simultaneous breath-by-breath analysis of expired gas fractions (Oxycon
Pro, Jaegar, Germany). Gas analysers and flow probes were calibrated prior to each test.
The results were expressed relative to body weight (ml/kg/min). Peak oxygen consumption
was calculated as the highest consecutive IS-second period of gas exchange data occurring
in the last minute before volitional exhaustion, which usually occurred due to leg fatigue or
breathlessness. Physiological criteria for assessment of V02peakincluded a levelling of
V02peakand/or a respiratory exchange ratio of 1.15 combined with a maximal heart rate at
least 90% of the age predicted maximal estimation (220-age) (Miller et aI., 1993).
4.7 Supervised Exercise Training Intervention
Prior to commencing the exercise intervention, all participants attended a thorough
familiarisation session at the Research Institute for Sport and Exercise Sciences (RISES)
gymnasium. In the first instance, participants were required to undertake 30 minutes of
moderate-intensity exercise consisting of treadmill walking/jogging, uprightlsemi-
recumbent cycling, cross-training or rowing. Participants were required to attend the
RISES gymnasium at least once a week during which time they wore a heart rate monitor
throughout (Polar Fitness, Polar Electro Oy, Finland) and were provided with full
supervision and guidance from a trained exercise physiologist (VSS). During these
sessions, participants were issued with a weekly progressive exercise programme that was
specific to their individual rate of progression. Exercise was primarily directed by heart
rate responses and utilisation of Borg's RPE scale (Borg, 1970). Training protocols were
specific to each participant's basal fitness level (Hutchison et al., 2011).
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During the initial 4 weeks of the intervention, participants underwent 30 minutes of
exercise three times a week at 30% of heart rate reserve (HRR). This routine continued
from week 5 to week 8, however, during this period exercise workload was modified so
that participants maintained a 45% HRR. From week 9 to week 12 participants continued
to maintain a workload of 45% HRR and the duration of each session increased to 45
minutes. Finally, from week 13 to week 16 the duration of each session remained at 45
minutes, workload increased to 60% HRR and participants underwent 5 exercise sessions
per week (Figure 4.7). Heart rate reserve was calculated as follows; (Max HR - Resting
HR) x Intensity) +Resting HR. Maximal and resting HR measures calculated during the
maximal oxygen consumption test completed prior to exercise training were utilised.
Figure 4.7 16-week moderate-intensity exercise training protocol.
Participants were closely monitored to ensure the maintenance of their individually
prescribed rate of perceived exertion and HRR. Furthermore, to facilitate maximum
compliance throughout the 16-week period, all participants utilised the Wellness Key
system, a software programme that enables remote and accurate tracking of exercise
activity. No dietary modifications were made throughout the course of the exercise
intervention, confirmed by use of a standard food diary.
4.8 Control Group
Women with peos in the control group received typical lifestyle advice provided at
clinical consultation. Participants were simply advised by their gynaecologist to modify
their lifestyle by losing weight and increasing their physical activity. Control participants
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received no contact with the research team at any point during the 16-week intervention
period.
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CHAPTERS
CONDUIT ARTERY ENDOTHELIAL
DYSFUNCTION IN OBESE WOMEN WITH PCOS
IS INDEPENDENT OF INTERNAL AND
VISCERAL ADIPOSE TISSUE
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5.1 Introduction
peDS is the most common female endocrine disorder associated with menstrual
dysfunction and obesity (Goodarzi et al., 2011). Aside from the clinical manifestations,
Chapter 3 provided robust evidence of conduit artery endothelial dysfunction, measured
using the flow-mediated dilation (FMO) technique (Thijssen et al., 2011), which appears to
be an inherent feature of peDS. Although, it was difficult to discern between the effects of
peDS, per se, and associated co-morbidities; an influence by BMI was evident. Given that
BMI cannot distinguish between adipose and lean tissue (Oreopoulos et al., 2011), the
direct impact of obesity on endothelial function in women with peDS, could not be
comprehensively assessed.
peDS is a multi-factorial syndrome with considerable heterogeneity in both clinical
characteristics and associated cardiovascular risk factors (Cussons et al., 2006). Insulin
resistance, dyslipidaemia and central obesity are common pathological features of peDS
which collectively constitute the metabolic syndrome and thus infer significant
cardiovascular disease (eVO) risk (Laws & Reaven, 1993). Specifically, Galvao et al.
(2012) reported exacerbated endothelial function across rising tertiles of insulin resistance
in obese individuals. Nevertheless, a previous study used multiple regression to show that
traditional cardiovascular risk factors explained less than 50% of the variation in FMO
between peDS and control women (Sorensen et al., 2006). Yet, the authors only utilised
BMI as a marker of obesity.
Indeed, different distributions of body fat, for example increased abdominal fat (Talbott et
al., 1995) or visceral adipose tissue (VAT) (Yildirim et al., 2003) in peDS relative to
controls could potentially contribute to the endothelial dysfunction in this patient group.
Generally, obesity is associated with a greater volume of subcutaneous adipose tissue
(SAT) and VAT. Although SAT accounts for a greater volume of total body adipose tissue,
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VAT is more metabolically active (Montague & O'Rahilly, 2000) and closely associated
with both insulin resistance (Hutchison et al., 2011) and cardiovascular risk (Cascella et al.,
2008a). VAT accumulation is also responsible for the up-regulation of ~ oxidation which
results in subsequent oxidative stress, the release of inflammatory cytokines and
adipokines, and a reduction of endogenous adiponectin, an anti-inflammatory substance
(Carmina et al., 2006; Cascella et al., 2008a; Carmina et al., 2009; Pepene, 2012).
Therefore, it is thought that excess VAT accumulation results in an exacerbated metabolic
phenotype of PCGS (Carmina et al., 2005) which may potentially induce a detrimental
effect on endothelial function.
In the one study which employed the non-invasive "gold standard" whole body magnetic
resonance imaging (MRI) technique to quantify VAT in women with PCGS, similar
volumes of VAT were reported between PCGS and weight-matched control women
(Barber et aI., 2008). Nevertheless, it remains unclear whether endothelial dysfunction is
evident in PCGS independent of fat deposition and/or distribution. Therefore, the aim of
this study was to examine the impact of adipose tissue volumes on endothelial dysfunction
in women with PCGS. It was hypothesised that conduit artery endothelial function would
be mediated by VAT.
5.2 Methods
5.2.1 Participants
Thirty five sedentary women with PCGS aged 28y (95% CI=26, 30) of BMI 32kg/m2 (95%
CI=27, 35) and 16 control women aged 32y (95% CI=30, 35) ofBMI 30kg/m2 (95% CI=25,
32) were recruited. For details of the inclusion and exclusion criteria please refer to
Chapter 4, General Methods. The study conformed to the Declaration of Helsinki and was
approved by the local research ethics committee. All participants were informed of the
methods before providing written informed consent.
86
5.2.2 Research Design
Participants reported to the laboratory on two separate occasions. Visit one included
anthropometric measurements, a fasting blood sample, assessment of brachial artery
endothelial function and a cardiorespiratory fitness test. Visit two involved whole body
magnetic resonance imaging (MRI) with proton magnetic resonance spectroscopy (1H
MRS). For details of the experimental procedures please refer to Chapter 4, General
Methods. A 30-year Framingham risk score was calculated for general CVD risk in all
participants (Pencina et aI., 2009). In control women, data was collected during the early
follicular phase of their menstrual cycle, and confirmed using reproductive hormone
profiles of follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone
and oestrogen. This was not feasible in women with PCOS, due to the erratic nature of
their cycles. Participants were asked to fast for 12-hours, abstain from alcohol and caffeine
for 24-hours and refrain from exercise for 48-hours prior to testing sessions. All
participants were studied at the same time of day to control for the impact of circadian
variation (Jones et aI., 2010).
5.2.3 Statistical Analysis
Analyses were performed using the Statistics Package for Social Sciences for windows,
version 17.0 (SPSS Inc. Chicago, IL, USA). The primary outcome variable for this study
was FMD (%) and the primary comparison was PCOS vs. control women. Based on the
data reported in Cascella et al. (2008a) between PCOS (n=200) and control women
(n=100), and using MINITAB 16; a sample size of 6 in each group will have 80% power to
detect a standardised difference in means of 2.2SD using a two group t-test with a 0.050
one-sided significance level. Firstly, all data were analysed for distribution and
transformed appropriately. Differences between PCOS and control women were analysed
using independent t-tests. Pearson's correlation coefficients (two-tailed) were calculated to
evaluate the relationship between FMD and other major variables; followed by a
87
comparison of slopes to identify differences between groups. Subsequently, FMD were
then analysed whilst statistically controlling for internal adipose tissue (lAT), VAT and
HOMA-IR as independent covariates. Logarithmically-transformed data were back
transformed to the original units and presented in the text as mean (95% Cl), unless
otherwise stated. Statistical significance was delimited at P<0.05 and exact P values are
cited (values of P of "0.000" provided by the statistics package are reported as "<0.00 I").
5.3 Results
5.3.1 Participant Characteristics
The characteristics of all PCOS and control participants are listed in Table 5.1. PCOS and
control women were similar in terms of age (P=O.l4), BMI (P=O.lO), waist circumference
(P=0.19) and cardiorespiratory fitness (P=O.2I). Women with PCOS demonstrated
elevated serum testosterone levels [l.Onmol/l (95% CI=0.6, 1.4), P<O.OOI] and depressed
sex hormone binding globulin (SHBG) [-12.2nmolll (95% CI=-24.3, -0.4), P=0.02]
compared with controls. Consequently, free androgen index was elevated in the PCOS
cohort [5.9% (95% CI=2.6, 9.1), P<O.OOI]. Lutenizing hormone (LH) was elevated in
women with PCOS compared with control women [4.9U/l (95% CI=l.2, 5.6), P=0.01].
5.3.2 Adipose tissue volume
Control women exhibited lower MRI (total body adipose tissue, lAT, SAT, VAT and
abdominal SAT) and IH MRS-derived (liver fat and intramyocellular lipid (IMCL))fat
volumes; however, none of these differences were statistically significant (P>0.05, Table
5.1).
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Table 5.1 Overall comparisons of PCOS and control women.
PCOS (n=352 Control {n=162 P
Clinical characteristics
Age (y) 28(26,30) 31(27,35) 0.14
BMI (kg/rrr') 32(30,35) 30(25,32) 0.10
Weight (kg) 90(82,96) 80(71,88) 0.10
Waist (cm) 102(96, 108) 95(85, 105) 0.19
V02 peak (ml/kg/min) 26.1(24.0, 28.2) 23.3(18.2,28.4) 0.21
Testosterone (nmol/l) 2.6(2.3, 2.8) 1.6(1.2, 1.9) <0.001
SHBG (nmol/lj] 29.4(24.8,35.0) 42.0(33.7,52.5) 0.02
FAIt 8.5(6.8, 10.5) 3.7(2.7,5.0) <0.001
FSH (U/l)t 5.0(4.4,5.7) 5.0(4.4,6.7) 0.48
LH (U/I)t 8.2(6.4, 10.7) 4.8(3.5,6.7) 0.01
Oestradiol (pmol/lr] 262(218,315) 253(162,394) 0.85
Progesterone (nmol/l)'] 2.7(2.2,3.7) 1.9(1.2, 2.8) 0.10
Framingham Risk (CHO 30-year risk) (%) 6.7(5.2,8.1) 8.7(4.6, 12.8) 0.23
Biochemical and metabolic parameters
ALT (U/I)t 21.5( 17.3, 26.8) 20.0(14.8,24.3) 0.49
Glucose (mmol/l) 4.6(4.5,4.8) 4.6(4.3,4.9) 0.89
Insulin (J.lIU/ml)t 17.3(14.9,20.0) 20.9(16.3,26.9) 0.17
HOMA-IRt 3.5(3.0,4.2) 4.3(3.2,5.7) 0.22
Cholesterol (mmol/I) 4.9(4.6,5.3) 4.7(4.2,5.1) 0.35
Triglycerides (mmol/lj+ 3.0(2.6,3.6) 2.9(2.3, 3.6) 0.70
HOL (mmol/l) 1.4(1.3, 1.5) 1.4(1.2, 1.6) 0.89
LOL (mmol/l) 3.0(2.7,3.3) 2.8(2.4, 3.1) 0.29
Chol:HDLratio 3.7(3.3,4.0) 3.5(2.9, 4.1) 0.47
MRI-measured Adipose Tissue Volumes
Total body fat (I) 46.2(41.0,51.4) 38.4(29.7,47.2) 0.10
IAT (I) 6.8(5.7, 7.9) 5.4(4.2,6.6) 0.13
SAT (I) 39.4(34.9,43.9) 33.1(25.1,41.0) 0.13
lAT:SAT ratio] 0.18(0.15, 0.20) 0.18(0.14,0.21) 0.97
VAT (I) 3.7(3.0,4.3) 2.9(2.1, 3.6) 0.16
Abdominal SAT (I) 14.1(12.2, 16.0) 11.0(7.8, 14.1) 0.08
VAT:abdominalSA T ratiot 0.28(0.23, 0.33) 0.29(0.22,0.37) 0.58
IH MR Spectroscopy
Liver fat (% CH21H20)t 4.3(1.8, 8.7) 1.6(0.2, 5.6) 0.17
Soleus IMCL (CH2/creatine)t 10.7(8.6, 13.2) 8.7(5.9, 12.8) 0.31
Tibialis Anterior IMCL (CH2/creatine)t 10.3(7.8, 13.6) 10.4(7.0, 15.3) 0.98
Vascular Function (brachial artery)
Flow-Mediated Dilation (%) 6.2(5.4, 7.0) 10.7(8.7, 12.8) <0.001
Baseline Diameter (mm) 0.34(0.32, 0.35) 0.33(0.31, 0.35) 0.80
Peak Diameter (mm) 0.36(0.34, 0.37) 0.37(0.34, 0.39) 0.49
Shear rate AVC (S-I x 103) 20.1(15.4,24.7) 21.1(13.6,28.5) 0.81
FMO-Mediated Time to Peak (s) 65.5(54.3, 76.7) 47.5(36.1,58.9) 0.05
GTN-Mediated Dilation (%) 21.3(18.9,23.7) 20.2(17.1,23.3) 0.58
GTN-Mediated Time to Peak (s2 386{350, 423) 343(304,381) 0.14
t Variables analysed after logarithmic transformation.
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5.3.3 Measures of Endothelial Function
Brachial artery FMD was impaired in women with peas compared with controls [-4.5%
(95% el=-6.3, -2.S), P<O.OOI, Figure 5.1]. No differences were observed in baseline
diameter, peak diameter or shear rate (P>0.49 Table 5.1). However, the time to reach peak
diameter was greater in women with peas [lS.0s (95% cr-o.i, 36.1), P=0.05, Table 5.1].
There was no significant difference between endothelium independent vasodilation [1.1 %
(95% eI=-3.0, 5.2), P=0.5S, Table 5.1] or time to peak diameter in response to GTN [44s
(95% Cl=JS, 102), P=0.14, Table 5.l].
P<O.OOI
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10 •-. • •~0 • I'-'
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4 • ••
2 •
0
PC OS Controls
Figure 5.1 Individual FMD data in women with peas and matched controls. Mean FMD%
indicated by red points.
5.3.4 FMD Correlations
There was no relationship between brachial artery FMD and MRI-derived lA T (r=0.04,
P=0.S5; r=-O.OS, P=0.75, Figure 5.2) or VAT (r=0.15, P=O.4O; r=-O.OI, P=0.9S, Figure 5.3)
in either peas or control women. Endothelial function did not correlate with traditional
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/eVD risk factors including HOMA-lR (r=O.24, P=0.20; r=O.02, P=O.95, Figure 5.4) and
insulin (r=O.22, P=O.25; r=O.l8, P=O.58), in women with peos or controls, respectively.
Moreover, a comparison of slopes between FMD and IAT (P=0.45, Figure 5.2), FMD and
VAT (P=O.54, Figure 5.3) and FMD and HOMA-lR (P=O.63; Figure 5.4) did not
significantly differ between peos and control women.
20 +PCOS .Controls
18 •
16
14 • • ••,-., •~ 12 ••• •0'-'
~ 10
~ • •
8 $. ~ ••• •.st • •6 .. • •
~ • • •4 • •• •2 • •
0
0 2 4 6 8 10 12 14 16
IAT (L)
Figure 5.2 The relationship between brachial artery FMD and lATin peos (r=O.04,
P=O.85) and control women (r=-O.08, P=O.75).
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Figure 5.3 The relationship between brachial artery FMD and VAT in peos (r=O.15,
P=OAO) and control women (r=-O.O1, P=O.98).
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Figure 5.4 The relationship between brachial artery FMD and HOMA-IR in peos (r=O.24,
P=O.20) and control women (r=-O.02, P=O.95).
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5.3.5 Analysis of Covariance
When FMD was adjusted for individual differences in IAT [-4.3% (95% el=-6.l, -2.4),
P<O.OOI], VAT [-4.4% (95% el=-6.3, -2.5), P<O.OOl] and HOMA-IR [-3.9% (95% ci-.
5.6, -2.1), P<O.OO 1], the differences in FMD between groups remained and were of similar
magnitude (Figure 5.5).
16
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Adjusted for IAT Adjusted for VAT Adjusted for HOMA
Figure 5.5 FMD responses of peos vs. matched control women following statistical
adjustment for IAT, VAT and HOMA-IR. Data is presented as mean±standard
deviation. *Significant difference between peos and controls (P<O.OO 1).
5.4 Discussion
The major finding of the current study was that women with peos exhibit reduced FMD
compared with control women and that this impairment was independent of adipose tissue
volume and insulin resistance. These data suggest that the inherent endothelial dysfunction,
which implies greater eVD risk, in women with peos is not related to global or regional
adiposity or insulin resistance. Therefore, FMD might be a useful independent prognostic
tool to assess eVD risk in this population.
Endothelial dysfunction was evident in women with peos compared with controls, which
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supports the findings from Chapter 3, and suggests an inherent impairment in FMD in
PCOS, that persists despite statistical adjustment for internal and visceral adipose tissue
volume. This finding seems somewhat surprising given that VAT is metabolically active
and excess VAT promotes increased circulating FFA and cytokines, (Panagiotakos et al.,
2005; Cascella et al., 2008a) which may contribute to the endothelial dysfunction.
Moreover, increased visceral fat thickness has been previously associated with endothelial
dysfunction in women with PCOS (Cascella et al., 2008a) although, to date, such studies
have quantified visceral adiposity using ultrasound which is highly operator dependent
(lacobellis, 2005). Conversely, differences in adipose tissue volume between women with
PCOS and controls of similar BMI were not evident in the current study, a finding which
supports a previous study using the gold standard non-invasive MRI technique (Barber et
al., 2008). Taken together, our data indicate that endothelial dysfunction in PCOS is not
explained by obesity.
Despite observing endothelial dysfunction in women with PCOS no differences in
'traditional' cardiovascular disease risk factors, including insulin resistance, were observed
between women with PCOS and control women. This is not surprising given that no
differences in VAT were evident, which is considered an accurate and independent bio-
marker for insulin resistance (Lord et al., 2006). This finding supports the extensive work
from Green and colleagues (Green et al., 2003; Green et al., 2008; Green, 2009; Green et
al., 2011) demonstrating that modification of traditional CVD risk factors does not explain
changes in endothelial function. A novel finding of the current study was that time to reach
peak arterial diameter following forearm ischemia was significantly greater in women with
PCOS. This suggests, for the first time, that a reduced NO bioavailability maybe a
mechanism for endothelial dysfunction in women with PCOS as opposed to delayed
relaxation at the level of the smooth muscle (Black et aI., 2008a).
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A possible alternative mechanism influencing FMD in peos is hyperandrogenism. In the
current study, both testosterone and free androgen index were elevated in women with
peos. EI-Kannishy et al. (20l0a) observed a negative correlation between brachial artery
FMD and testosterone in women with peos, but such an adverse impact of androgens on
FMD is not a unanimous finding (Empen et al., 2012). A notable limiting factor when
evaluating previous studies investigating endothelial function in women with peos is the
different criteria utilised for diagnosis. In this study, women with peos were recruited
based on diagnosis using the Rotterdam criteria for which hyperandrogenism is not a
fundamental requirement, unlike the 'classical' National Institute of Health (NIH) or
Androgen Excess Society (AES) criteria. Although, 28 out of the 35 recruited women
fulfilled all three Rotterdam criteria and thus met the 'classical' NIH criteria, it is
important to note that only 22 of the 35 exhibited biochemical hyperandrogenism and the
remaining 6 exhibited clinical signs of elevated androgens (e.g. acne, hirsutism). Previous
studies that have explored the possibility of hyperandrogenism being an important
pathological feature of peos, have all used specific biochemical parameters including
testosterone (EI-Kannishy et al., 2010a) and free androgen index (Jones et aI., 2012) as
markers of hyperandrogenism. Specifically, free testosterone is now considered the most
sensitive biomarker supporting the diagnosis of peos (Sharquie et al., 2007). Therefore, it
is plausible that androgens impose a direct impact on the vessel wall, as steroid receptors
exist within the vasculature. Nevertheless, this hypothesis remains unconfirmed and the
impact of androgens on vascular reactivity in women with peos warrants further specific
investigation.
One major advantage of this study is the continuous and simultaneous measurement of
arterial diameter and blood flow velocity in combination with edge detection and wall
tracking software, which is independent of observer bias and in accordance with the latest
guidelines for the assessment of FMD (Thijssen et al., 2011). This technique enables the
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continuous measurement of the shear stress stimulus, absolute arterial diameters and time
to reach peak diameter. Another noteworthy strength of this study was the utilisation of IH_
MRS and whole body MRI, which are considered to be the most sensitive, non-invasive
methods to quantify liver fat and VAT, respectively. The study incorporated a suitable
control group, which were similar in terms of age, BMI and cardiorespiratory fitness.
In summary, the current data suggest that impaired brachial artery endothelial function in
obese women with peos is independent of VAT, IAT or insulin resistance. Further
exploration of potential moderators of FMD and endothelial function in peos women with
a hyperandrogenic phenotype, determined by raised free testosterone, is warranted.
96
CHAPTER6
EXERCISE TRAINING IMPROVES CONDUIT
ARTERY ENDOTHELIAL FUNCTION IN OBESE
WOMEN WITH PCOS
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6.1 Introduction
Internationally, peos affects up to 10% of women according to the 'classical' National
Institute of Health (NIH) criteria (Azziz et al., 2004) and up to 20% using the broader
Rotterdam criteria (Broekmans et al., 2006) and is therefore the most common
endocrinopathy in females of reproductive age. peos is associated with several cardio-
metabolic pathologies including obesity, insulin resistance, impaired glucose tolerance or
type 2 diabetes, non-alcoholic fatty liver disease (NAFLO), dyslipidaemia and
hypertension (Goodarzi et al., 2011). Therefore, it might be expected that there would be
an increased prevalence of cardiovascular disease (eVO) in this population. A plethora of
studies using surrogate markers of evo risk in women with peos, including measures of
vascular structure (Arikan et al., 2009) and function (Chapter 3 and 5) and biochemical
serum concentrations of evo risk markers (Toulis et al., 2011), have supported this
association. The relationship between peos and evo is further evidenced by a recent
meta-analysis of follow-up studies in women with peos which detailed a -2 fold
increased risk of arterial disease compared with non-peOS women, specifically coronary
heart disease and stroke (de Groot et al., 2011).
Lifestyle modification has been endorsed by the Androgen Excess (AE)-peOS Society as a
first line treatment in the prevention of evo (Wild et al., 20 I0). Existing exercise-
intervention studies in women with peos have reported the beneficial effects of exercise
on reproductive function (Palomba et al., 2008), obesity (Moran et al., 2009b) and
cardiorespiratory fitness (Vigorito et al., 2007) but theeffect of exercise on cardiovascular
parameters remains unknown.
Exercise training has been found to improve endothelial function in patients who exhibit
similar risk factors to women with peos, for example in patients with type 2 diabetes
(Maiorana et al., 2001). Indeed, exercise induced improvements in endothelial function
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have been reported to occur both prior to, and independent of, changes in traditional
markers of eVD risk, such as BMI and blood pressure, in patients with coronary artery
disease (Walsh et al., 2003), hypertension (Higashi et al., 1999) and type 2 diabetes
(Maiorana et al., 2001). Nevertheless, it is unknown how the inherent endothelial
dysfunction in women with peas is modified by interventions. For instance, a study
assessing the effects of metformin on arterial stiffness, a surrogate measure of vascular
function, reported that enhanced vascular function may be independent of changes in
insulin resistance (Agarwal et al., 2010). Therefore, the aim of this study was to determine
the effects of a 16-week moderate-intensity aerobic exercise-training programme,
compared with a control intervention, on endothelial function in obese women with peas.
It was hypothesised that 16-weeks of supervised exercise training would enhance FMD to
a greater degree than conventional care.
6.2 Methods
6.2.1 Participants
Seventeen women with peas aged 28y (95% eI=25, 31), of BMI 33kg/m2 (95% eI=30,
35) were recruited from a reproductive clinic. For details of the inclusion and exclusion
criteria please refer to Chapter 4, General Methods. The study conformed to the
Declaration of Helsinki and was approved by the local research ethics committee. All
participants were informed of the methods before providing written informed consent.
6.2.2 Research Design
Participants reported to the laboratory on two separate occasions. Visit one included
anthropometric measurements, a fasting blood sample, assessment of brachial artery
endothelial function and a cardiorespiratory fitness test. Visit two involved whole body
magnetic resonance imaging (MRI) with proton magnetic resonance spectroscopy eH
MRS). For details of the experimental procedures please refer to Chapter 4, General
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Methods. A 30-year Framingham risk score was calculated for general CVD risk in all
participants (Pencina et al., 2009). It was not feasible to control for menstrual cycle phase
in women with pcas, due to the erratic nature of their cycles. Participants were asked to
fast for 12-hours, abstain from alcohol and caffeine for 24-hours and refrain from exercise
for 48-hours prior to testing sessions. All participants were studied at the same time of day
to control for the impact of circadian variation (Jones et al., 2010).
Ten [n=10, 27y (95% CI=23, 32), 31kg/m2 (95% CI=28, 34)] women with rcos received
a 16-week programme of supervised moderate-intensity aerobic exercise training while
seven women [n=7, 29y (95% CI=24, 35), 35kg/m2 (95%CI=31, 40)] were used as a
control group. All patients underwent the physiological measurements at baseline and
after the 16-weeks of intervention. For details regarding the respective interventions please
refer to Chapter 4, General Methods.
6.2.3 Statistical Analyses
Analyses were performed using the Statistics Package for Social Sciences for windows,
version 17.0 (SPSS Inc. Chicago, IL, USA). The primary outcome variable for this study
was FMD (%) and the primary comparison was the effect of exercise vs. conventional care.
Based on the data reported in Chapter 3 between pcas and control women, and using the
NQUERY (Statistical Solutions, Ireland) software, it was estimated that a sample size of 9
in the exercise and CC groups will have 80% power to detect a difference between groups
in mean change of 4%. Firstly, all data were analysed for distribution and transformed
appropriately. For the comparison of the exercise vs. conventional care intervention, delta
(6) change from pre-intervention was calculated (Vickers & Altman, 2001) and analysed
using generalised estimating equations (GEE), with pre-exercise data as a covariate. The
analysis approach based on GEE is considered a powerful and robust approach to the
analysis of repeated measures data (Ballinger, 2004). Logarithmically-transformed data
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were back-transformed to the original units and presented in the text as mean (95% Cl),
unless otherwise stated. Statistical significance was delimited at P<0.05 and exact P values
are cited (values of P of "0.000" provided by the statistics package are reported as
"<0.00 I").
6.3 Results
Women with PCOS that completed 16-weeks of exercise training demonstrated 91%
compliance to exercise sessions.
6.3.1 Cardiorespiratory fitness
There was a greater improvement in cardiorespiratory fitness following exercise training
compared with CC [4.7ml/kglmin (95% CI=I.4, 7.9),P=0.005, Figure 6.1].
6.3.2 Biochemical Characteristics
Exercise training and conventional care did not affect fasting glucose [-0.02mmolll (95%
CI=-0.09, 0.13), P=0.78, Table 6.1] or insulin [-4.4~IU/ml (95% CI=-11.3, 2.5), P=0.21,
Table 6.1] differently; therefore, there was no difference in HOMA-IR following the
respective interventions [-0.6 (95% CI=-2.2, 1.0), P=0.47, Figure 6.1]. Cholesterol reduced
to a greater degree following exercise training compared with the conventional care group
[-0.20mmol/l (95% CI=-0.28, 0.04), P=0.01,]. LOL also decreased following exercise
training [-0.7mmol/l (95% CI=-1.I, -0.3), P=O.OOI,Table 6.1].
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6.3.3 Vascular Measurements
Mean FMD demonstrated a greater improvement following exercise training compared
with conventional care [3.5% (95% CI=1.7, 5.1), P>O.OO], Figure 6.1]. Time to reach peak
diameter was faster following exercise training [-16.8seconds (95% CI=-32.1, 1.5),
P=O.09]. There was no difference in baseline or peak arterial diameter or shear rate
between interventions (P>O.05). All vascular data are summarised in Table 6.2.
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Figure 6.1 Individual FMD delta change scores for following exercise training and
conventional care. Mean values indicated by red data points.
6.3.4 Hepatic and Abdominal Fat Deposition
There was no significant difference in change in liver fat between exercise-trained and
conventional care [-0.5% eH21H20 (95% eI=-1.2, 0.6), P=0.56, Table 6.1]. Similarly,
there was no significant difference in weight, BMI, waist circumference muscle fat, VAT
or abdominal SAT between interventions (P>0.05; Table 6.1).
6.4 Discussion
The novel finding of the current study was that supervised moderate-intensity exercise
training induced a greater improvement in brachial artery endothelial function in women
with peos when compared with a conventional care control group. Importantly, this
improvement in endothelial function occurred independent of changes in weight, liver fat,
VAT or insulin resistance. These data suggest that weight loss should not be the primary
goal of women with peos and advocates the utilisation of supervised exercise training as
a management strategy, capable of improving endothelial dysfunction in women with
rcos.
Endothelial dysfunction is the earliest manifestation of atherosclerotic disease, which
precedes morphological impairment or clinical symptoms and is evident in women with
peos, independent of age or BMI (Chapter 3). To our knowledge, this is the first study to
assess the effect of exercise training on endothelial function in women with peos.
Previously, surrogate markers, such as carotid intima-media thickness (cIMT), have been
utilised to evaluate eVD risk in women with peos. A recent study investigated the effect
of a one-year lifestyle intervention, consisting of nutritional advice, exercise training and
behavioural therapy, in obese adolescent peos girls and reported a reduced cIMT in those
girls who achieved significant weight loss only (Lass et al., 2011). Nevertheless, the
authors could not distinguish between the effects of exercise, diet, behavioural therapy and
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weight loss, nor did they include a control group for comparison. Importantly, the present
findings indicate that moderate-intensity aerobic exercise, that meets the current
recommended physical activity guidelines of the American College of Sports Medicine
(Gordon, 2009) and the American Heart Association (Pearson et al., 2002), can induce
significant improvements in brachial artery FMD, an early and prognostic marker of future
cardiovascular risk, in the absence of weight loss.
There were no significant changes in parameters of obesity including BMI, waist
circumference, or abdominal adipose tissue volumes following exercise training in these
obese women. This finding is in contrast to Hutchinson et al. (2011) who reported a
significant decrease in BMI, VAT and insulin resistance following 12 weeks of exercise,
which consisted of alternated moderate-intensity continuous exercise (-70% V02peak)and
high intensity intermittent exercise (-90-100% V02peak)for-Bhr/week, in women with
PCOS. It is plausible that an exercise training stimulus of higher intensity may have
elicited changes in adipose tissue volume within the current study. Nevertheless, given that
the exercise intervention enhanced FMD in women with PCOS to a level comparable to
control women of similar age and BMI (Chapter 3), and body composition does not
mediate the difference in FMD observed in PCOS and control women, as observed in
Chapter 5, it is unlikely that changes in body composition within the current study would
induce a greater increase in FMD.
The exercise intervention did cause significant reductions in total and LDL cholesterol,
which provides further evidence for the positive effect of exercise training on CVD risk
reduction in PCOS. Nevertheless, insulin resistance and liver fat did not significantly
change with exercise training. Intriguingly both insulin resistance and liver fat (liver fat
<5.56%) (Szczepaniak et al., 2005) were not deemed elevated in these women prior to the
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intervention. One explanation for the data being within normal healthy limits may be
related to the criteria employed to diagnose PCOS in these women. National Institute of
Health (Zawadzki & Dunaif, 1992) and Androgen Excess Society (Azziz et al., 2006)
definitions describe more obese and insulin resistant phenotypes of PCOS, due to
hyperandrogenism being an integral criteria for diagnosis (Moran & Teede, 2009).
Biochemical hyperandrogenic PCOS represents a distinct metabolic phenotype
characterised by an increased risk of hepatic steatosis and insulin resistance (Jones et al.,
2012, Journal of Clinical Endocrinology and Metabolism, under review).
Hyperandrogenism is not an essential feature of the Rotterdam (2004) criteria; as indicated
within the current study population, as only 11 of the 17women demonstrated biochemical
hyperandrogenism. Nevertheless, it is unlikely that androgens contributed to the exercise-
induced improvement in FMD observed in the present study, as testosterone and free
androgen index did not change following either exercise or conventional care.
Given that the exercise-induced improvement in endothelial function was independent of
concomitant changes in body composition, insulin resistance or lipid profiles, the current
data suggests that exercise has a direct effect on the endothelium in women with PCOS. It
is widely accepted that the FMD response in conduit vessels is endothelium-dependent and
nitric oxide-mediated (Doshi et al., 2001). Exercise training has been shown to promote
NO bioavaiIability by reducing the number of oxygen free radicals, and up-regulating
endothelial NO synthase in CAD patients (Hambrecht et al., 2003). Moreover, it has been
hypothesised that episodic increases in arterial shear stress, induced by exercise, act as a
key stimulus to these functional adaptations of the endothelium which decrease
atherosclerotic risk (Green, 2009). Elevated CVD (hypertension) and event (stroke) risk in
this population is vascular in origin and therefore a direct effect on vascular function with
exercise is crucial in these women.
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One limitation of this study was that the intervention was based on patient choice rather
than a more robust randomisation method to allocate the intervention. This limitation is
highlighted in the fact that conventional care group had a greater BMI compared to the
exercise group. However, given that we employed a robust covariate control analysis
technique that incorporate adjustments for differences in baseline measurements and
significant changes in BMI did not occur with the intervention, it is unlikely to have an
impact on the study outcome. Nevertheless, there are several noteworthy strengths in the
methodology of this study. No alteration in diet enabled comprehensive assessment of the
impact of exercise training exclusively on endothelial function in peos. Finally, the study
was appropriately powered to detect a difference of 4% in the primary variable (FMD)
between the control and exercise groups.
In summary, the current data suggest that supervised moderate-intensity exercise training
enhances endothelial function in women with peos. Given that FMD has been found to
provide independent prognostic information relating to eVD risk, these data support the
utilisation of supervised exercise training as a cardio-protective strategy for vascular
dysfunction, and primary prevention for eVD risk independent of weight loss, in women
with peos.
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CHAPTER 7
NITRIC-OXIDE MEDIATED CUTANEOUS
MICROVESSEL FUNCTION IS IMPAIRED IN
POLYCYSTIC OVARIAN SYNDROME AND CAN
BE IMPROVED WITH EXERCISE TRAINING
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7.1 Introduction
Polycystic ovarian syndrome (PCOS) is associated with endothelial dysfunction in conduit
arteries (Chapters 3 & 5) and a higher prevalence of hypertension in the post-menopausal
period (Schmidt et al., 2011). Cutaneous microvessel vasodilator function can be used as a
surrogate of generalised microvascular function and provides a translational model to
investigate pre-clinical disease (Holowatz et al., 2008). A small number of studies have
investigated cutaneous endothelial function in PCOS and have reported cutaneous
microvessel dysfunction (Lakhani et al., 2005; Alexandraki et al., 2006). However, the
most recent study reported that cutaneous microvessel dysfunction was only apparent
during insulin infusion in obese PCOS and control women, but not in lean PCOS or control
women, thereby suggesting that obesity, not PCOS per se, was associated with
microvascular dysfunction (Ketel et al., 2008).
The studies examining microvascular function in women with PCOS have challenged the
endothelium of cutaneous microvessels using iontophoresis-mediated infusion of
acetylcholine (ACh). Although ACh is a precursor of cutaneous vasodilatation, this
technique is limited as the vasodilator response is not exclusive to nitric oxide (NO)
(Holowatz et al., 2005). Rather, intradermal infusion of a competive NO inhibitor is the
only method which allows for the accurate assessment of the NO contribution to cutaneous
vasodilation (Cracowski et aI., 2006). To date, no research study has examined the
contribution of NO to cutaneous microvessel dysfunction in obese women with PCOS,
which is surprising considering endothelium-derived NO acts as a stimulus to anti-
atherogenic adaptations (Green, 2009).
It has been established that NO-mediated vasodilation in the cutaneous microvessels is
influenced by fitness in healthy individuals (Black et al., 2008b) and that exercise training
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improves NO-mediated cutaneous microvascular function (Black et al., 2008b; Simmons et
al., 2011). Despite lifestyle modification being recommended as a primary prevention
strategy of eVD in peos (Chapter 6; Wild et al., 2010), no study to date has investigated
the impact of exercise training on cutaneous microvascular function in women with peos.
Therefore, the aims of the current study were to (i) examine NO-mediated cutaneous
microvascular function in obese peos and control women using intradermal microdialysis
allowing for the infusion of a specific NO antagonist; and (ii) to examine the effect of a 16-
week moderate-intensity aerobic exercise training programme on NO-mediated cutaneous
microvascular function in women with peos. It was hypothesised that (i) the NO-
mediated vasodilator response to gradual local heating would be impaired in women with
peos compared with controls and (ii) that supervised exercise training would induce an
improvement.
7.2 Methods
7.2.1 Participants
Eleven women with rcos [29y (95% cr-zs, 34), 34kg/m2 (95% Cl=Sf), 38)] and six
matched controls [29y (95% Cl=Zl , 37), 34kg/m2 (95% el=28, 39)] were recruited. For
details of the inclusion and exclusion criteria please refer to Chapter 4, General Methods.
The study conformed to the Declaration of Helsinki and was approved by the local
research ethics committee. All participants were informed of the methods before providing
written informed consent.
7.2.2 Research Design
Participants reported to the laboratory on two separate occasions. Visit one included
anthropometric measurements, a fasting blood sample, assessment of cutaneous NO-
mediated vasodilator function (described below) and a cardiorespiratory fitness test. Visit
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two involved whole body magnetic resonance imaging (MRI) with proton magnetic
resonance spectroscopy eH MRS). For details of the experimental procedures please refer
to Chapter 4, General Methods. In control women, data was collected during the early
follicular phase of their menstrual cycle, and confirmed using reproductive hormone
profiles. This was not feasible in women with PCOS, due to the erratic nature of their
cycles. Participants were asked to fast for 12 hours, abstain from alcohol and caffeine for
24 hours and refrain from exercise for 48 hours prior to testing sessions. All participants
were studied at the same time of day to control for the impact of circadian variation (Jones
et al., 2010)
Following baseline assessment, six women with PCOS [30y (95% CI=22, 37), 31kg/m2 (95%
CI=25, 37)] enrolled onto a 16-week supervised moderate-intensity aerobic exercise
training programme. Upon completion, physiological assessments were repeated. For
details regarding the exercise training intervention please refer to Chapter 4, General
Methods.
7.2.3 Microdialysisfibre instrumentation
All intradermal microdialysis assessments were performed in a quiet, temperature-
controlled laboratory. Upon arrival, participants were instrumented and cannulation for
microdialysis probe insertion was undertaken (~ 15 minute). Once the participant was
seated comfortably in a custom-designed bed, the right arm was supinated and supported
for insertion of microdialysis fibres. The insertion sites were marked on the skin and cold
packs were applied as a form of local anaesthesia. Two 2I-gauge needles were inserted
~5cm apart from one another and ~O.3-I.Omm beneath the epidermal surface, allowing
threading and placement of two microdialysis fibres (Linear 30, CMA Microdialysis Ltd,
Stockholm, Sweden), containing 10mm long 6kDa membranes. The needles were then
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removed and the embedded fibres were perfused with saline solution at a rate of
Sul/minute using a micro-infusion pump (Model 11 plus, Harvard Apparatus, MA, USA).
Following this, integrated laser Doppler probes (Model 413, Periflux 5001 System,
Perimed AB, Sweden) combined with local heating disks (Perimed 455, Stockholm,
Sweden) set at 33°C were placed above both embedded microdialysis fibres sites. Laser
Doppler flowmetry (LDF) uses a laser diode to emit a monochrome light at a penetrative
depth of approximately 1mrrr'. The incident monochrome light reflects off moving blood
cells causing a shift in the returning wavelength (Doppler effect) from which estimates of
cutaneous blood flux (the concentration of red blood cells x their velocity) can be made.
Consequently, LDF enables sensitive and quantifiable detection of relative changes in
cutaneous blood flow in response to a given stimulus.
7.2.4 Physiological NO-mediated vasodilatation
Following a -90 minute equilibration period, the skin surrounding both microdialysis
probes was gradually heated, using local heating disks, from 33 to 42°C at a rate of O.SOC
per 2.5 minute (45 minute). Thereafter, both sites were continuously heated at 42°C for a
further 30 minutes. This gradual heating protocol was used to minimise the impact of
heating on axon reflexes, which are less NO-mediated than slow heating component
responses (Minson et al., 2001; Houghton et al., 2006). Saline solution was infused
throughout the protocol in one site and L-NG-monomethyl arginine (L-NMMA, 10mM,
Sill/minute, Clinalfa, Bachem, Germany) infused through the second, from 30 minutes
prior to the onset of heating. Sodium nitroprusside (SNP, S6mM, Mayne Pharma,
Warwickshire, UK), a potent NO donor, was infused at the end of the protocol for 30
minutes (Minson et al., 2002; Cracowski et al., 2006) to initiate peak vasodilatation
(Figure 2).
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Figure 7.1 Schematic of the physiological (localised heating) NO-mediated vasodilatation
protocol.
7.2.5 Assessment offorearm skin bloodflow
To obtain an index of cutaneous blood flow, cutaneous red cell flux was measured by
placing integrated laser-Doppler probes, each consisting of a seven-laser array, above each
microdialysis site. The laser-Doppler probe signals were continuously monitored via an
online software chart recorder (PSW, Perimed, Sweden). At each designated study time-
point (2.5 minute intervals), cutaneous blood flow was assessed by averaging laser-
Doppler flux, measured in perfusion units (PU), over a stable 30-second period. These data
were subsequently converted to cutaneous vascular conductance (Cv'C), calculated as
LDF/MAP (PU mmHg), where MAP was derived from contemporaneous automated blood
pressure measures (Dinamap; GE Pro 300V2) in the contralateral arm. Values were then
expressed relative to the maximal eve achieved during infusion of 56mM of SNP at
42°C, as %CVCmax; this is the preferred method of data expression adopted in the
literature (Cracowski et al., 2006). Data during the incremental heating were calculated
and presented at each temperature (every O.soC from 33°C to 42°C) for both the saline and
L-NMMA microdialysis sites. The contribution of NO was calculated by subtracting
individual L-NMMA data from saline data collected simultaneously.
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7.2.6 Statistical Analysis
Analyses were performed using the Statistics Package for Social Sciences for windows,
version 17.0 (SPSS Inc. Chicago, IL, USA). Firstly, all data were analysed for distribution
and transformed appropriately. All differences in baseline characteristics between groups
(PCOS vs. control women) were compared using independent t-tests and changes
following exercise training (pre-post exercise) were examined using paired t-tests.
Cutaneous blood flow data was presented as %CVCmax and analysis was performed on this
normalised data (Cracowski et al., 2006). Logarithmicallytransformed data were back-
transformed to the original units and presented in the text as mean (95% Cl), unless
otherwise stated. Statistical significance was delimited at P<0.05 and exact P values are
cited (values of P of "0.000" provided by the statistics package are reported as "<0.001").
To ensure successful increase in NO production with the local heat stimulus and successful
blockade of NO production, saline and L-NMMA data were individually compared using a
two factor (site vs. temperature) analysis of variance (ANOVA). A two factor (group vs.
temperature) repeated measures ANOVA was also employed to compare the contribution
of NO (saline %CVCmax minus L-NMMA %CVCmax at equivalent time points)
to %CVCmax response at baseline (PCOS vs. control) and following exercise training (pre-
post exercise). Statistically significant interactions between these two factors were
followed-up with least significant difference (LSD) approach to multiple comparisons
(Rothman, 1990; Pemeger, 1998).
7.3 Results
7.3.1 pcas vs. controls: Clinical Characteristics
PCOS and control women were similar in terms of age, BMI and cardiorespiratory fitness
(Table 7.1). Women with PCOS displayed elevated testosterone [O.8mmolll (95% CI=O.3,
1.4), P=0.006] and free androgen index [4.0mmol/l (95% CI=O.l, 7.9), P=0.05] compared
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with control women.
Table 7.1 Baseline characteristics of PCOS (n=ll) and control women (n=6).
PCOS Controls P
Clinical Characteristics
Age (y) 29(25,34) 29(21,37) 0.98
BMI(kg/m2) 34(30,38) 34(28,39) 0.84
Weight (kg) 91.2(79.3, 103.0) 91.0(75.7,106.3) 0.98
Waist circumference (cm) 106(97, 115) 106(89, 123) 0.98
V02peak (mllkg/min) 26.1(23.0,29.2) 25.3(17.4,36.3) 0.44
FSH (iu/I) 4.9(3.8,6.0) 5.7(4.0, 7.3) 0.37
LH (iu/I) 11.0(6.2,15.8) 7.6(3.5, 11.7) 0.31
Progesterone (nmol/lj+ 3.0(2.1,4.2) 2.2(0.8, 6.1) 0.41
Oestradiol (pmol/l)'] 253(188, 340) 244(127,467) 0.89
Testosterone(nmol/I) 2.8(2.4, 3.2) 1.9(1.5,2.4) 0.006
Free Androgen Index (%) 9.7(7.0, 12.5) 5.7(3.8, 7.7) 0.05
SHBG (nmol/lr] 31.3(21.5, 45.7) 40.0(26.6,48.7) 0.59
Biochemical and metabolic
parameters
ALT (iu/l)t 22.3(14.5,34.5) 24.5(10.4,57.7) 0.80
Glucose (mmol/I) 4.6(4.4, 4.8) 4.6(4.4,4.9) 0.97
Insulin (pmol/lrt 17.5(13.2,23.2) 18.8( 12.0, 29.5) 0.75
HOMA-IRt 3.6(2.6, 4.9) 3.9(2.5,6.3) 0.71
Cholesterol (mmol/l)'] 5.0(4.5,5.5) 5.1(4.5,5.7) 0.89
Triglyceride (mmolll)t 2.0(1.2, 3.2) 2.2(1.3, 3.7) 0.74
HDL (mmol/lrt 1.4( 1.2, 1.7) 1.4(1.1, 1.7) 0.79
LDL (mmolll) 3.0(2.6,3.4) 3.1(2.6,3.6) 0.74
Chol:HDL ratio 3.5(2.9,4.2) 3.7(2.4,4.9) 0.82
MRI measured adipose
tissue volumes
IAT (I) 6.0(4.5, 7.4) 7.1(5.9,8.4) 0.25
SAT (I) 39.8(31.7,47.9) 41.5(33.7,49.3) 0.77
VAT (I) 3.2(2.3,4.1) 3.8(2.9,4.7) 0.35
Abdominal SAT (I) 14.2(11.1, 17.2) 13.7(10.3, 17.1) 0.83
Total body fat (I) 45.8(36.9,57.7) 48.6(41.5, 55.8) 0.64
IH MR Spectroscopy
Liver fat (% CH21H20)t 3.7(0.6, 12.8) 4.0(1.6, 8.6) 0.93
Soleus IMCL (CH2/creatine)t 11.1 (7.1, 17.5) 15.5(8.3,29.0) 0.33
Tibialis Anterior 13.2(8.1,21.5) 9.8(3.3,29.2) 0.50
1MCL( CH2/creatine}t
+Variables analysed following logarithmic transformation.
7.3.2 pcas vs. Controls: Incremental Heating
In response to local heating, %CVCmax increased steadily at microdialysis sites infused
with either saline or L-NMMA in all participants at baseline (P<O.OOI, Figure 7.2).
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However, the site infused with L-NMMA displayed a reduced %CVCmax in both PCOS
and control women (P=O.OOI, Figure 7.2); suggesting that the cutaneous response to local
heating in both groups was, at least in part, mediated by the NO dilator system. A
significant microdialysis site x temperature interaction was evident (P<O.OOI, Figure 7.2)
and pairwise comparisons revealed significant differences between the saline and L-
NMMA site from 39-42°C in PCOS and 40-42°C in control women (P<0.05).
7.3.3 PCOS vs. Controls: Nitric Oxide Contribution to Incremental Heating
There was a significant group by temperature interaction between PCOS and control
women (P=O.OI, Figure 7.2). Subsequent pairwise comparisons revealed that there was a
significant difference in NO contribution between PCOS and control women when the
incremental heating protocol reached 42°C [-17.5%CVCmax{95% CI=-33.3, -1.7), P=0.03]
and subsequently when the heating stimulus remained at 42°C for both 5 (peak) [_
16.0%CVCmax (95% CI=-32.5, 0.6), P=0.05] and 30 minutes (prolonged) [-15.4%CVCmax
(95% CI=-29.6, -1.3), P=0.04] (Figure 7.2).
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Figure 7.2 The effect of incremental and prolonged heating on cutaneous blood flow in the
saline and L-NMMA microdialysis site in -(A) PCOS and (B) control women and (C) the
contribution of NO (saline %CVCmax minus L-NMMA %CVCmax) in women with PCOS
and matched controls. Data is presented as mean±standard deviation. *Significant
difference between L-NMMA and saline sites (P<O.05).
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7.3.4 Impact of exercise training in pcas: Clinical Characteristics
Women with PCOS demonstrated 90% compliance to exercise sessions. BMI, AT volumes
and biochemical parameters were similar following the exercise intervention (P>0.05,
Table 7.2). The exercise intervention increased cardiorespiratory capacity by 5.0ml/kg/min
(95% CI=0.9, 9.2, P=0.03, Table 7.2).
Table 7.2 Changes in the characteristics of women with PCOS following supervised
exercise training (n=6).
Pre Exercise Post Exercise /).Change p
Clinical Characteristics
BMI(kglm2) 31(25,37) 30(24,37) -0.3( -1.6, 1.0) 0.54
Weight (kg) 79.6(65.5,93.7) 78.8(64.3, 93.2) -0.8( -4.2, 2.6) 0.56
Waist circumference (cm) 100(84, 117) 96(77, 116) -3.8(-10.4,2.8) 0.20
V02peak (ml/kg/min) 27.1(21.6,32.5) 32.1 (24.0, 40.2) 5.0(0.9,9.2) 0.03
FSH (iu/lr] 5.6(2.8, 8.4) 5.3( 1.8, 8.8) -0.3(-3.1, 2.5) 0.75
LH (iu/lj] 11.9(2.2, 21.6) 9.6(2.2, 17.0) -0.4( -6.9, 2.2) 0.22
Progesterone (nmol/I) 2.5(1.6,3.4) 1.3(0.5, 2.0) -1.3( -2.8, 0.3) 0.08
Oestradiol (pmolll) 232(126,337) 197(129,264) -35(-133,63) 0.34
Testosterone( nmolll) 2.5(1.7,3.3) 2.4(1.6, 3.2) -0.1(-0.7,0.5) 0.64
Free Androgen Index (%)t 8.5(6.2, 10.7) 9.2(7.0, 11.5) O.7(-1.2, 2.8) 0.15
SHBG (nmol/I) 29.0(21.7,36.3) 24.5(17.4,33.6) -4.4(12.3, 7.5) 0.51
Biochemical and metabolic
parameters
ALT (iu/lj] 38.5(10.9,67.9) 41.8(17.9,61.4) 3.3(-18.1,24.6) 0.66
Glucose (mmolll) 4.5(4.1, 4.9) 4.8(4.4,5.1) 0.3(-0.4, 0.9) 0.32
Insulin (pmol/l)t 17.1(8.7,25.5) 23.9(12.8,35.1) 6.8(-6.4, 19.9) 0.24
HOMA-IRt 3.5(0.6, 5.5) 4.0(0.3, 7.7) 0.6(-0.6, 4.8) 0.80
Cholesterol (mmol/I) 4.8(4.4, 5.3) 4.6(4.1,5.1) -0.2(-1.0,0.6) 0.43
Triglyceride (mmolll) 1.3(0.1, 2.5) 1.5(0.1, 2.8) 0.2(-0.4,0.7) 0.44
HDL (mmolll) 1.3(0.8, 1.8) 1.2(0.4, 1.0) -0.1 (-0.4, 0.2) 0.35
LDL (mmolll) 3.1(2.5,3.6) 2.7(2.4, 3.0) -0.3( -1.0, 0.4) 0.23
Chol:HDL ratio 4.0(2.7,5.3) 4.3(2.7,5.8) 0.3(-1.3, 1.8) 0.64
MRI measured adipose tissue
volumes
IAT (I) 4.7(3.0,6.3) 4.4(2.7,6.0) -0.3( -2.1, 1.5) 0.70
SAT (I) 30.7(20.9,40.5) 29.8(19.0,40.5) -1.0(-3.6, 1.7) 0.38
VAT (I) 2.4(1.5, 3.2) 2.5(1.4,3.7) 0.2( -0.8, 1.1) 0.65
Abdominal SAT (I) 11.7(7.3, 16:0) 11.3(6.4, 16.1) -0.4( -1.4, 0.6) 0.36
Total body fat (I) 35.2(24.3, 46.2) 34.3(21.5,47.0) -1.0( -5.2, 3.3) 0.56
IU MR Spectroscopy
Liver fat (% CH2/HP)t 1.5(0.2, 2.3) 0.4(0.1, 1.1) -0.4( -0.8, 0.6) 0.21
Soleus IMCL (CH2/creatine)t 17.1 (5.6, 28.6) 16.2(4.5,27.9) -0.9(-15.4, 13.6) 0.88
Tibialis Anterior 8.6(5.1, 14.5) 13.4(7.4,24.3) 4.8(0.6,9.8) 0.28
IMCQCH2/creatine 2t
t Variables analysed following logarithmic transformation.
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7.3.5 Impact of exercise training in pcas: Incremental heating
Prior to and following exercise training, cutaneous blood flow increased in response to
local heating in both the microdialysis sites infused with saline and L-NMMA (P<O.OOI,
Figure 7.3), suggesting that the cutaneous response to local heating was at least in part,
mediated by the NO dilator system. There was a significant interaction (microdialysis site
x temperature) pre and post exercise training (P<O.OOI, Figure 7.3). Pairwise comparisons
revealed differences between sites from 36-42°C pre exercise and 36.5-42°C post exercise
(P<0.05).
7.3.6 Impact of exercise training in PCOS: Nitric Oxide Contribution to Incremental
Heating
A significant intervention x temperature interaction was evident in NO contribution
to %CVCmax with exercise training (P<O.OOI, Figure 7.3). NO contribution to incremental
heating was greater post-exercise when incremental heating reached 36.5°C up to 42°C [_
I9.4%CVCmax (95% CI=-38.4, -0.4), P=0.05] and subsequently when the heating stimulus
remained at 42°C for both 5 (peak) [-I 9.6%CVCmax (95% CI=-34.9, -4.3), P=0.02] and 30
minutes (prolonged) [-17.1%CVCmax (95% CI=-32.1, -2.2), P=0.03] (Figure 7.3).
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Figure 7.3 The effect of incremental and prolonged heating on cutaneous blood flow in the
saline and L-NMMA microdialysis site in women with PCOS (A) pre and (B) post exercise
training and (C) the contribution of NO (saline %CVCmax minus L-NMMA %CVCmax) pre
and post exercise training. Data is presented as mean±standard deviation. *Significant
difference between L-NMMA and saline sites (P<O.05).
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7.3.7 Maximal cutaneous vascular responses during infusion of 56mM SNP at 42 QC
The 30 minute infusion of 56mM SNP combined with local heating at 42°C was similar
between the L-NMMA and saline microdialysis sites in PCOS [-0.2CVC (95% CI=-0.7,
0.3), P=OA4] and control women [OACVC (95% CI=-1.4, 2.2), P=0.60] at baseline.
Similarly, exercise training did not alter maximal cutaneous conductance in both the L-
NMMA [OACVC (95% CI=-0.8, 1.6), P=OA2] or the saline sites [0.02CVC (95% CI=-I.I,
1.1), P=0.97].
Discussion
The novel findings of the present study were that cutaneous NO-mediated microvascular
dysfunction was evident in obese PCOS compared with control women and that moderate-
intensity exercise training improved cutaneous NO-mediated function in women with
PCOS. These data indicate that obese women with PCOS exhibit impaired cutaneous NO-
mediated microvessel function in response to local heating compared with controls of a
similar age and BMI; and that moderate-intensity aerobic exercise training is capable of
improving cutaneous vasodilation, evidenced by an improved vasodilator response to local
heating.
This is the first study to examine the contribution of NO to microvessel vasodilation in
obese women with PCOS, which is surprising considering endothelium-derived NO acts as
a stimulus to anti-atherogenic adaptations (Green, 2009). Previous studies in women with
PCOS have investigated cutaneous vasodilation in response to iontophoresis-mediated
infusion of ACh which is primarily mediated by prostaniods (Khan et al., 1997; Noon et al.,
1998) and does not elicit a significant contribution from NO (Holowatz et aI., 2005). The
NO-mediated vasodilator pathway plays a crucial role in the control of cutaneous
endothelial function (Giles et al., 2012), and the stimulus of localised heating at 42°C has
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been reported to elicit the greatest contribution of NO (up to 70%) to the vasodilator
response (Kellogg et al., 1999; Minson et al., 2001). Moreover, intradermal infusion of L-
NMMA, a potent NO blocker (Goldsmith et al., 1996) during gradual heating is the
optimal technique to evaluate the cutaneous NO system (Cracowski et al., 2006).
Therefore, whilst the previous data suggest cutaneous microvessel dysfunction is evident in
peos (Lakhani et al., 2005; Alexandraki et al., 2006), and this impairment may be related
to obesity (Ketel et al., 2008). The data from the current study, utilising the most up-to-
date and appropriate technique, indicate that obese women with peos display a reduced
bioavailability of NO resulting in impaired cutaneous microvessel vasodilation compared
with obese control women. It is plausible that such NO-mediated microvessel dysfunction
in peos may contribute to increased eVD, specifically the higher prevalence of
hypertension in women with peos observed during the menopausal years (Schmidt et ai.,
2011).
Testosterone and free androgen index were elevated in women with peos within the
current study and could be postulated as a potential explanation for microvessel
dysfunction. Previous research studies have suggested that testosterone impairs
endothelium-dependent vasodilation in conduit vessels (Herman et al., 1997; Karakitsos et
al., 2006). In contrast, the impact of testosterone on the cutaneous vessels is unclear.
Lakhani et al. (2005) observed microvessel dysfunction in hyperandrogenic women with
peos, but the impairment remained following statistical adjustment for testosterone.
Furthermore, Sokolnicki et al. (2007a) reported that the administration of exogenous
testosterone did not alter cutaneous microvessel response to gradual local heating in older
men. Nevertheless, the impact of clinical and biochemical hyperandrogenism on cutaneous
microvessel function, specifically sex hormone binding globulin (SHBG) and the active
aspect of testosterone in peos (i.e. free testosterone), warrants further investigation.
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This is also the first study to demonstrate that exercise training in peos is capable of
improving cutaneous NO-mediated microvessel vasodilation in response to local heating.
The data demonstrates that 16-weeks of moderate-intensity aerobic exercise induced an up-
regulation of endogenous NO contribution to local heating, indicative of an improvement
in cutaneous endothelial-dependent function. Since the endothelial-independent pathway
was unaltered with exercise training, as indexed by maximal cutaneous responses
following infusion of a NO donor, the current data indicates that the exercise-induced up-
regulation of NO reflects changes in cutaneous microvascular function, independent of
changes in maximal vasodilator capacity. These findings may be of clinical relevance
given that NO-mediated microvessel vasodilation improved to levels similar to those
observed in non-peOS controls following exercise training. Specifically, this finding
provides support to the utilisation of lifestyle modification (exercise) as the first-line
prevention strategy in reducing eVD risk in peos.
Exercise has previously been reported as an effective intervention to improve cutaneous
microvessel function in aged sedentary individuals, in that exercise training induced an
increase in NO-mediated cutaneous vasodilation measured using intradermal microdialysis
of N-nitro-L-arginine methyl ester (L-NAME) during local heating (Black et al., 2008b).
The authors postulated that the up-regulation of NO bioavailability may be a function of
enhanced cardiorespiratory fitness. Similarly, within the current study the improved NO-
mediated cutaneous vasodilation observed in women with peos was coupled with an
improvement in cardiorespiratory fitness. An alternative but not mutually exclusive
mechanistic explanation could be related to the increases in microvascular shear stress
associated with repeated bouts of exercise (Green et aI., 2010). Indeed, shear stress has
been shown to up-regulate eNOS production in conduit arteries (Hambrecht et aI., 2003),
and limiting the increase in shear stress during exercise (using cuff inflation on one arm),
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has been shown to prevent increases in cutaneous microvascular function when compared
to normal patterns of shear stress in an uncuffed arm (Green et aI., 2010).
The exercise stimulus in the current study did not elicit any changes in clinical
characteristics, biochemical parameters or adipose tissue volumes of women with PCOS,
supporting the hypothesis that exercise training induced a direct therapeutic effect on the
microvascular endothelium. It is plausible that an exercise training stimulus of higher
intensity may have elicited changes in adipose tissue volume and thus elicited further
improvements in microvascular function. However, Middlebrooke et al. (2006)
administered 6 months of relatively high intensity exercise raining (70-80% Hkmax) in
type 2 diabetic patients and observed no changes in cutaneous microvessel function in
response to either iontophoretically-applied ACh or localised heating to 42°C.
Notwithstanding the technique utilised and the different population (which included males)
in that study, high-intensity exercise training may not be a suitable stimulus to enhance
cutaneous microvessel function. Indeed, the authors postulated that the inefficacy of high-
intensity exercise to induce changes in microvascular function may be due to increased
oxidative stress during higher intensity exercise resulting in a reduction in NO
bioavailability (Goto et aI., 2003).
There are several methodological issues that warrant consideration. Previous studies using
intra-dermal microdialysis have infused L-NAME, a more specific NO blocker (Black et
al., 2008b) rather than L-NMMA. Nevertheless, L-NMMA has been reported to elicit a
comparable inhibitory effect of NO-mediated dilation in a study employing whole body
heating (Dietz et al., 1994). Furthermore, the inclusion of a non-exercising control group,
ideally via a randomised controlled allocation method for comparison, would have enabled
a direct comparison to conventional clinical care.
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In summary, these data indicate that women with PCOS exhibit a reduced bioavailability
of NO, evidenced by a reduced NO-mediated cutaneous vasodilator response to local
heating, and that cutaneous vasodilator function can be improved via the up-regulation of
the anti-atherogenic molecule NO. These findings advocate the utilisation of exercise
training as a preventative strategy for microvascular dysfunction and primary prevention
for hypertension in women with PCOS.
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CHAPTER8
SYNTHESIS OF FINDINGS
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8.1 Aims and Objectives
The research work described In the present thesis was designed to investigate
cardiovascular health in women with polycystic ovarian syndrome (peOS) and to establish
whether supervised exercise training could ameliorate the increased risk of cardiovascular
disease (eVO) observed in this patient group. Specifically, the studies examined nitric
oxide (NO)-mediated endothelial function in both the conduit arteries and cutaneous
microvessels of women with peos and explored, for the first time, the impact of internal
adipose tissue volume, insulin resistance and fitness on conduit artery endothelial function.
Additionally, this thesis investigated whether a supervised moderate-intensity aerobic
exercise-training programme induced a therapeutic effect on NO-mediated conduit artery
and cutaneous microvessel vasodilator function.
8.2 Major Findings
8.2.1 pcas and conduit artery endothelialfunetion
The systematic review and meta-analysis detailed in Chapter 3 found that brachial artery
flow-mediated dilation (FMO), a strong and independent predictor of future cardiovascular
events, is impaired in women with peos compared with matched controls. The analysis
suggested that BMI may be a contributing factor to the endothelial dysfunction observed in
this clinical population; however, given that BMI cannot distinguish between adipose and
lean tissue, a regionalised effect of fat deposition and/or distribution could not be
disregarded. Chapter 5 went on to demonstrate that conduit artery endothelial dysfunction
in women with peos was independent of adipose tissue volume and insulin resistance.
Taken together, these studies provide compelling evidence that endothelial dysfunction is
an inherent aspect of peos and advocates the utilisation of FMO as a valuable prognostic
tool for evo in this patient group.
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8.2.2 pcas and cutaneous microvessel endothelial function
In line with the findings in conduit vessels, Chapter 7 found that obese women with peos
demonstrate impaired cutaneous NO-mediated microvessel function in response to local
heating compared with controls of a similar age and BMI. The infusion of a specific NO
blocker via intradermal microdialysis enabled accurate quantification of the precise
contribution of NO to the vasodilator response of cutaneous microvessels. This study
therefore confirmed that obese women with peos display a reduced bioavailability of the
anti-atherogenic molecule NO compared with obese control women and therein exhibit a
reduced endogenous defence against eVD.
8.2.3 Exercise training and endothelial function in pcas
Chapter 6 demonstrated that following 16-weeks of supervised moderate-intensity aerobic
exercise training, brachial artery FMD improved in women with peos. Importantly, this
improvement in conduit artery endothelial function was greater than that observed
following current UK conventional care guidelines. Chapter 7 illustrated that the same
exercise intervention enhanced the NO contribution to cutaneous microvessel vasodilation
in obese women with peos. A noteworthy observation of these studies was that exercise
training normalised the PeOS-induced deficits in both conduit artery and cutaneous
microvessel endothelium-dependent vasodilation to values observed in healthy control
women of a similar age and BMI. Furthermore, these improvements in endothelial function
occurred independent of weight loss and without any change in tradition eVD risk factors
including insulin resistance, blood lipids and obesity. Taken together, these studies suggest
that exercise training ameliorates the NO-mediated endothelial dysfunction consistently
observed in the peos population. Given that direct measures of vascular endothelial
function have been found to provide independent prognostic information relating to eVD
(Green et al., 2011), these data support the utilisation of supervised exercise training as a
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cardio-protective strategy for endothelial dysfunction and primary prevention of CVD in
this high-risk patient group.
8.3 General Discussion
Findings from Chapter 3 and Chapter 5 demonstrate that endothelium-dependent
vasodilation, evidenced by brachial artery FMD, is impaired in women with PCOS
compared with control women of a similar age and BMI. Endothelium-derived NO is a
vital component in the endogenous defence against CVD (Vallance et al., 1989) and has
been reported to be the primary mediator of the FMD response (Joannides et al., 1995;
Doshi et al., 2001). Therefore, the impaired FMD that appears to be inherent in women
with PCOS is indicative of diminished NO vasodilator function and thus an increased risk
of CVD. Critically, Chapter 5 demonstrated that conduit artery endothelial dysfunction in
women with PCOS is also independent of visceral and internal adiposity (Figure 8.1). This
finding was somewhat surprising given that visceral adipose tissue (VAT), and associated
insulin resistance, has been found to be an accurate and independent predictor of CVD
(Despres, 2007). Together, these data demonstrate that PCOS may provoke a detrimental
impact on conduit artery endothelial function, which exceeds the adverse effect of global
obesity, adipose tissue volume and sedentary behaviour (Figure 8.1). Therefore, reduced
endothelial function in conduit vessels may contribute to the -2 fold increased risk of
coronary heart disease and stroke exhibited in women with PCOS, which is not explained
by an increased prevalence of obesity (de Groot et al., 2011).
Assessment of the cutaneous microvasculature in women with PCOS is logical given that
dysfunction of the microvessels is an earlier sentinel of CVD risk than conduit artery
dysfunction (Roustit & Cracowski, 2012). The skin is a large, readily accessible organ that
provides a suitable site for the assessment of peripheral microvascular reactivity. To date,
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the skin has been used as a model of microcirculation to investigate vascular mechanisms
in a variety of diseased states (Sax et al., 1987; Levy et al., 2001; Sokolnicki et al., 2007b;
Levy et al., 2008) and is now regarded as a valid model of generalised microvascular
function (Holowatz et al., 2008). Specifically, the use of gradual localised heating and
manipulation of NO, through the use of specific and potent NO blockers, enables
researchers to mechanistically assess cutaneous microvascular function. The data presented
in Chapter 7 revealed that obese women with PCOS exhibit a reduced bioavailability of
NO compared with obese controls and thus confirm the indirect assessment of the NO
system in conduit vessels employed in Chapters 5 and 6. These findings indicate that
PCOS mediates an adverse effect on NO bioavailability that exceeds the detrimental
impact caused by obesity and sedentary behaviour. A recent review in Microcirculation
suggests that impaired microvascular function causes an increase in peripheral resistance,
which may potentially initiate the pathogenic progression of hypertension (De Boer et al.,
2012). Therefore, cutaneous microvessel dysfunction may, at least in part, account for the
increased prevalence of hypertension observed in women with PCOS during post-
menopausal years, which is not explained by traditional CVD risk factors (Schmidt et al.,
2011).
Chapters 6 and 7 demonstrate that exercise training improves conduit vessel and cutaneous
microvessel function to a similar level to that exhibited by age- and BMI-matched control
women (Chapters 3 and 5), thus normalising the intrinsic CVD risk observed in women
with PCOS. This up regulation of endogenous NO bioavailability at different levels of the
arterial tree is indicative of an improvement in systemic endothelium-dependent
vasodilator function. Crucially, the endothelium-independent pathway was unaltered with
exercise training, as indexed by maximal conduit artery and cutaneous microvessel
vasodilation in response to a potent NO donor. Therefore, these data confirm that exercise
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training promotes an up-regulation of NO bioavailability rather than an increased
sensitivity to NO within vascular smooth muscle. In addition, it is interesting to note that
the exercise-induced improvement in brachial artery FMD was ~58%, whereas the
improvement in NO contribution to cutaneous microvessel vasodilation at 42°e was over
100%. This suggests that the microcirculation is more plastic and therefore amenable to
exercise-mediated enhancement compared with conduit vessels. Previous studies have
demonstrated that interventions in clinical populations who display similar symptoms to
women with peDS, which improve endothelial-dependent vasodilator function, are
associated with improved morbidity and mortality (Green et al., 2003).
Previous studies have postulated that the up-regulation of NO bioavailability may be a
function of enhanced cardiorespiratory fitness (Black et al., 2008b; Black et al., 2009).
Chapters 6 and 7 found that improved NO-mediated vasodilation observed in obese
women with peDS was coupled with an improvement in cardiorespiratory fitness.
However, there was no statistical correlation between the exercise-induced change in
cardiorespiratory fitness and endothelial function suggesting that these adaptations
occurred independent of one another. An alternative, but not mutually exclusive
mechanistic explanation could be related to the exercise-induced episodic increases in
vessel shear stress which act as a key stimulus to functional adaptations of the endothelium
and consequently decrease atherosclerotic risk (Green, 2009). Indeed shear stress has been
shown to up-regulate eNOS production in conduit arteries (Hambrecht et al., 2003), and
limiting the increase in shear stress during exercise (using cuff inflation on one arm) has
been shown to prevent increases in cutaneous microvascular function when compared to
normal patterns of shear stress in an uncuffed arm (Green et al., 2010).
Enhanced FMD and cutaneous microvessel vasodilation was evident independent of
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statistically significant reductions in BMI, waist circumference, VAT and insulin resistance.
A previous study that employed 12 weeks of alternated training which comprised of both
moderate and high intensity exercise reported a significant reduction in VAT (-11 %) and
improved insulin regulation (Hutchison et al., 2011). Therefore, it is plausible that exercise
training interventions of higher intensity may have mediated an improvement in traditional
risk factors associated with the metabolic syndrome and thereby prompt further
cardiovascular health benefits. Nevertheless, the current studies demonstrate that exercise
training of moderate-intensity is capable of improving conduit and microvessel endothelial
function independent of changes in obesity status, body composition and insulin resistance.
Therefore, this data suggests that exercise training exerts a direct effect on the endothelium
in this high-risk patient group.
The fact that exercise training has induced a cardioprotective effect in the absence of a
reduction in traditional cardiovascular risk factors is not a novel phenomenon.
Cumulatively, the findings detailed within this thesis corroborate the extensive work of
Green and colleagues who have shown that NO-mediated endothelium dysfunction can be
directly targeted by exercise training in several populations, despite minimal changes in
traditional cardiovascular risk factors including blood lipids, insulin regulation and
hypertension (Maiorana et al., 2001; Green et al., 2003; Walsh et al., 2003; Green et al.,
2004; Watts et al., 2004; Green et al., 2008; Green, 2009). Based on these studies and the
work of others, Joyner and Green (2009) have postulated that exercise results in -40%
more "protection" from CVD than that which is predicted based on exercise-mediated
changes in traditional CVD risk factors.
The work contained within this thesis therefore provides a powerful health message.
Although epidemiological studies in women with PCOS relating to cardiovascular
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mortality are limited, the literature relating to eVD risk in these women is irrefutable. The
experimental studies described have added to the understanding of underlying mechanisms
pertaining to the inherent endothelial dysfunction exhibited by women with peos, as
shown in Figure 8.1. Nevertheless, given that peos is the most common endocrine
disorder in pre-menopausal women coupled with the fact that current conventional care
guidelines fail to induce a reduction in eVD risk, these findings have the potential to
impact clinical practice and subsequently improve cardiovascular health this high-risk
group.
Inflammation
mediated endothelial
dysfunction
Insulin ResistanceHyperandrogenism/
peos Phenotype
Liver Fat
Figure 8.1 A schematic of potential influencing factors on endothelial function in women
with peos, specifically highlighting those that have been ruled out by the work contained
within this thesis.
8.4 Implications
peos is unique in that it is not a product of Westernised society and, unlike obesity, the
metabolic syndrome, non-alcoholic fatty liver disease and type 2 diabetes, peos is not
reversible. Whilst the phenotypic expression ofPeOS can be exacerbated by poor lifestyle,
the prevalence of peos is approximately ~ 10% worldwide and is independent of race or
environmental factors (Goodarzi et al., 2011). Therefore, the management of risk factors is
the sole treatment option to improve eVD prognosis in women with peos.
The research work undertaken in this thesis contextualises the extent of eVD risk that is
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evident in women with peos. Recently published robust risk ratios indicate that the risk of
a cardiovascular event increases by 21% for every 1 standard deviation (=3.5%) decrease
in FMD (Inaba et al., 2010). Although this previous meta-analysis did not specifically
involve women with peos, it is interesting to note that Chapters 3 and 5 evidenced a
mean FMD reduction of 3.5-4.5% in peos compared with control women. Indeed, these
data suggest that the risk of cardiovascular events is -21 % higher in women with peos
compared with controls. Moreover, Chapters 6 and 7 are the first studies to demonstrate
the therapeutic effects of supervised exercise training on conduit artery and cutaneous
microvessel health in women with peos. Supervised exercise training mediated a mean
improvement in FMD of 4.0% in women with peos which, according to the prognostic
data published by Inaba et al. (2010), normalises the eVD risk observed at baseline.
Additionally, the beneficial effects of exercise training on cutaneous microvascular
function may act as a potential mechanism to diminish the prevalence and progression of
insulin resistance and hypertension (De Boer et al., 2012).
Taken together, given that higher levels of NO confer anti-atherogenic benefit, the findings
of this thesis have potentially important implications for the prevention of atherosclerosis,
coronary heart disease and stroke in women with peos and imply that supervised exercise
prescription should be recommended as a cardioprotective management strategy.
8.5 Methodological considerations and limitations
There are several noteworthy strengths in the methodology of this thesis. Firstly, the
utilisation of the most current peer-reviewed guidelines and technology to assess FMD
(Thijssen et al., 2011) coupled with the use of custom designed edge detection and wall
tracking analysis software in Chapters 5 and 6, maximised the accuracy, validity and
prognostic index of this measurement tool. Secondly, application of IH-MRS and whole
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body MRI, throughout Chapters 5-7, is considered to be the most sensitive, non-invasive
method to quantify liver fat and adipose tissue volumes. Third, the use of intradermal
microdialysis enabled the delivery of a specific NO blockade and vasoactive agonist to
directly interrogate the microcirculation, which allowed for accurate evaluation of
cutaneous NO-mediated microvascular function. Additionally, a rigorous inclusion and
exclusion criteria was adhered to throughout the experimental chapters and importantly all
women with PCOS were recruited from the same clinic following in-depth diagnosis.
Finally, the absence of a significant change in dietary intake during the interventions
employed in Chapters 6 and 7 enabled the assessment of exercise training effects
exclusively.
Nevertheless, limitations within this thesis are apparent. One limitation of this thesis was
the methods employed to assess insulin resistance in Chapters 5-7; the use of an oral
glucose tolerance test (Abdul-Ghani et aI., 2007) or a two-stage hyperinsulinaemic-
euglycaemic clamp, with infusion of deuterated glucose (Shojaee-Moradie et al., 2007),
would have facilitated a more comprehensive assessment of hepatic and peripheral
(skeletal muscle) insulin sensitivity. Chapter 6 was limited with the intervention being
based on patient choice rather than a randomised allocation method to the interventions;
however, a robust covariate control analysis technique that incorporated adjustments for
differences in baseline measurements was utilised. The positive within-groups result
reported in Chapter 7 regarding the effect of exercise training on NO-mediated
microvascular function requires confirmation from future studies incorporating a no-
exercise control group. Menstrual phase cannot be determined in women with PCOS which
is potentially problematic when assessing cardiovascular parameters. In order to control for
this we assessed reproductive hormone profiles during all testing sessions in order to
determine menstrual phase biochemically.
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8.6 Future Direction
There are several potential areas of future research which have emerged from the studies
detailed within this thesis. Firstly, the heterogeneous nature of PCOS and lack of a
judicious definition is problematic when interpreting data and generalising findings. The
most recent consensus statement regarding the diagnosis of PCOS was released from the
Androgen Excess Society (Azziz et al., 2009). The authors defined PCOS first and
foremost as a hyperandrogenic disorder and, indeed, the effect of excess androgens on
CVD risk and endothelial function in women with PCOS is currently unknown (Figure 8.1).
Nevertheless, unpublished data derived from the work contained within this thesis indicate
that biochemical hyperandrogenism worsens the metabolic phenotype of PCOS and thus
may negatively influence endothelial function (Jones et al., 2012, Journal of Clinical
Endocrinology and Metabolism, under review). Examination of phenotypic expression and
endothelial function in women with PCOS based on the presence of biochemical
hyperandrogenism is therefore warranted in order to accurately determine the adverse
effects caused by increased endogenous androgen availability. Specifically, the effect of
free testosterone on endothelial function in this population would be an interesting area for
future study.
Future research should endeavour to explore the effect of potential modifying variables on
endothelial function in women with PCOS (Figure 8.1). Insulin resistance cannot be
disregarded as a potential contributor to endothelial dysfunction in women with PCOS as
the sole measure of insulin resistance employed within this thesis was HOMA-IR.
Therefore further scrutiny of the relationship between insulin resistance and endothelial
function in women with PCOS is warranted. Specifically, the utilisation of the "gold
standard" two-stage hyperinsulinaemic-euglycaemic clamp, with infusion of deuterated
glucose (Shojaee-Moradie et al., 2007), would provide the most in-depth assessment of
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hepatic and peripheral insulin sensitivity. Although, endothelial dysfunction in women
with peas is not attributable to VAT per se, excess accumulation of VAT has been
reported in exacerbated phenotypes of peas (Yildirim et al., 2003). Elevated VAT
contributes to increased adipocyte lipolysis that results in augmented secretion of
circulating free fatty acids (FFA) and adipokines (Fujioka et al., 1987). VAT is unique in
that it is drained via the portal vein and thus excess circulating FFA derived from VAT are
absorbed by the liver which leads to increased secretion of inflammatory cytokines and,
consequently, a state of chronic inflammation (Matsuzawa et al., 1995). Therefore, the
relationship between endothelial function and less overt pathological features such as
inflammation may be warranted (Figure 8.1).
Finally, lifestyle modification is difficult to maintain in the absence of supervision; yet, for
exercise training to be clinically endorsed as a credible intervention to reduce the risk of
eVD, it is essential that the beneficial effects are evident long-term. Thus, research
investigating whether exercise-induced improvements In endothelial function are
sustainable and long-term in women with peas is vital.
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Bishop Goss Complex
Victoria Building
Rose Place
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L3 3AN
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Facsimile: 01513302075
31 October 2008
Dr Daniel Cuthbertson
Clinical Senior Lecturer and Honorary Consultant Physician
University of Liverpool
Clinical Sciences Centre
University Hospital Aintree
Liverpool
L97AL
Dear Dr Cuthbertson
Full title of study: Insulin resistance and polycystic ovarian syndrome
(PCOS)
OSIH1 005/72REC reference number:
Thank you for your letter of, responding to the Committee's request for further information
on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the
above research on the basis described in the application form, protocol and supporting
documentation as revised, subject to the conditions specified below.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form.
Confirmation of approval for other sites listed in the application will be issued as soon as
local assessors have confirmed they have no objection.
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start of
the study.
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Management permission or approval must be obtained from each host organisation prior to
the start of the study at the site concerned.
Management permission at NHS sites ("R&D approval") should be obtained from the
relevant care organisation(s) in accordance with NHS research governance arrangements.
Guidance on applying for NHS permission is available in the Integrated Research
Application System or at http://www.rdforum.nhs.uk.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Version Date
Participant Consent Form: Insulin resistance and Polcysit Ovarian 1 01 July 2008
Syndrome (PCOS) Part Fat
Participant Information Sheet: Insulin Resistance, Visceral fat and 1 01 July 2008
Endothelial Dysfunction in Polycystic Overian Syndrome (PCOS) Part
2 Vascular Assessment
Participant Information Sheet: Insulin Resistance and Polycystic 1 01 July 2008
Ovarian Syndrome (PCOS) Part 3a: The Effects of Exercise
Intervention on Insulin Resistance and Visceral Fat
Participant Information Sheet: Insulin Resistance, Visceral fat and 1 01 July 2008
Endothelial Dysfunction in Polycystic Ovarian Syndrome (PCOS): Part
3b Effect of Exercise Intervention on Vascular Function
Participant Information Sheet: Insulin resistance and Polycystic Ovarian 1 01 July 2008
Syndrome (PCOS) Part 1: Quantifying Visceral Fat
Letter of invitation to participant
Covering Letter 15 July 2008
Protocol 1 01 July 2008
Investigator CV
Application 5.6 16 July 2008
letter from dependant review
letter for pcos
Schematic of Protocol
Response to Request for Further Information
Participant Consent Form 01 October 2008
Participant Information Sheet 2 01 October 2008
Participant Information Sheet 2 01 October 2008
Advertisement
Statistician Comments
Covering Letter
Protocol
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001) and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK.
After ethical review
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Now that you have completed the application process please visit the National Research
Ethics Website> After Review
You are invited to give your view of the service that you have received from the National
Research Ethics Service and the application procedure. If you wish to make your views
known please use the feedback form available on the website.
The attached document "After ethical review - guidance for researchers" gives detailed
guidance on reporting requirements for studies with a favourable opinion, including:
• Notifying substantial amendments
• Progress and safety reports
• Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the light of
changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve
our service. If you would like to join our Reference Group please email
referencegroup@nres.npsa.nhs.uk.
I 081H100S/72 Please quote this number on all correspondence
With the Committee's best wishes for the success of this project
Yours sincerely
Dr Tej Purewal
Chair
Email: adam.lewis@liverpoolpct.nhs.uk
Enclosures: "After ethical review - guidance for researchers"
Site approval form
Copy to: Ms Adele Maggs
Faculty of Medicine Support
University of Liverpool
Systematic Appraisal of Quality for Observational Research (SAQOR)
Adaptedfrom Ross et al. (2011)
Sample
Is the sample recruited using an established diagnostic criterion? (NIH/AESlRotterdam)
Yes No
Are the patients recruited from the same clinic? (Specific mention required)
Yes No
Is a power calculation reported?
Yes No
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Are the entry criteria and exclusions clearly stated?
Yes No
Sample: /4
Control Group
Are the control group easily identified? (i.e. clear distinction- non-PCOS)
Yes No
I. Are the control group matched for age and BM!?
~ Yes No
2. If groups are unmatched, have statistical differences been controlled for? (covariate)
Yes No
Control group: /2
Quality of Assessment
Does the FMD technique utilise 5 minutes of cuff occlusion?
Yes No
Does the study utilise an ultrasound imaging technique?
Yes No
Does FMD analysis utilise callipers (averaging more than one measure) or edge detection
software?
Yes No
FMD technique: /3
Confounding Variables
Were specific medications excluded? (Notably OCP or other synthetic hormone)
Yes No
Was existing CVD excluded? (specific mention required, hypertension, history ofMI,
CVD etc.)
Yes No
Were smokers excluded? (specific mention required)
Yes No
Confounding variables: /3
Reporting Data
Is an explanation for missing data is given?
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Yes No
Data are clearly and accurately presented? (i.e. mean±SD/SE/CI, exact P values cited).
Yes No
!!!!!!l 12
Study Quality 114
0-3 Very low quality
4-7 Low quality
8-11 Adequate quality
11+ High quality
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